| 抗体药名 | 针对靶点 | 产品名称 | 产品编号 |
| Enapotamab | AXL | Human ALX Antibody (Enapotamab, Research Use) | NBR-0001 |
| Tilvestamab | AXL | Human ALX Antibody (Tilvestamab, Research Use) | NBR-0002 |
| Alsevalimab | VTCN1 | Human B7-H4 Antibody (Alsevalimab, Research Use) | NBR-0003 |
| GSK2857916 | TNFRSF17 | Human BCMA Antibody (GSK2857916, Research Use) | NBR-0004 |
| LFB patent anti-BDCA-2 | BDCA-2 | Human BDCA-2 Antibody (LFB patent anti-BDCA-2, Research Use) | NBR-0005 |
| BIIB059 | BDCA-2 | Human BDCA-2 Antibody (BIIB059, Research Use) | NBR-0006 |
| Inebilizumab | CD19 | Human CD19 Antibody (Inebilizumab, Research Use) | NBR-0007 |
| Tafasitamab | CD19 | Human CD19 Antibody (Tafasitamab, Research Use) | NBR-0008 |
| Rituximab | CD20 | Human CD20 Antibody (Rituximab, Research Use) | NBR-0009 |
| Obinutuzumab | CD20 | Human CD20 Antibody (Obinutuzumab, Research Use) | NBR-0010 |
| Cixutumumab | IGF-1R | Human IGF-1R Antibody (Cixutumumab, Research Use) | NBR-0011 |
| Inotuzumab | CD22 | Human CD22 Antibody (Inotuzumab, Research Use) | NBR-0012 |
| Varlilumab | CD27 | Human CD27 Antibody (Varlilumab, Research Use) | NBR-0013 |
| Brentuximab | CD30 | Human CD30 Antibody (Brentuximab, Research Use) | NBR-0014 |
| Vadastuximab | CD33 | Human CD33 Antibody (Vadastuximab, Research Use) | NBR-0015 |
| Naratuximab | CD37 | Human CD37 Antibody (Naratuximab, Research Use) | NBR-0016 |
| Daratumumab | CD38 | Human CD38 Antibody (Daratumumab, Research Use) | NBR-0017 |
| Magenta patent anti-CD5 | CD5 | Human CD5 Antibody (Magenta patent anti-CD5, Research Use) | NBR-0018 |
| Persongen patent anti-CD7 | CD7 | Human CD7 Antibody (Persongen patent anti-CD7, Research Use) | NBR-0019 |
| Vorsetuzumab | CD27L / CD70 | Human CD27L / CD70 Antibody (Vorsetuzumab, Research Use) | NBR-0020 |
| Amivantamab | c-Met / HGFR | Human c-Met / HGFR Antibody (Amivantamab, Research Use) | NBR-0021 |
| Telisotuzumab | c-Met / HGFR | Human c-Met / HGFR Antibody (Telisotuzumab, Research Use) | NBR-0022 |
| Onartuzumab | c-Met / HGFR | Human c-Met / HGFR Antibody (Onartuzumab, Research Use) | NBR-0023 |
| Pamrevlumab | CTGF | Human CTGF Antibody (Pamrevlumab, Research Use) | NBR-0024 |
| Ipilimumab | CTLA-4 | Human CTLA-4 Antibody (Ipilimumab, Research Use) | NBR-0025 |
| Quetmolimab | CX3CL1 | Human CX3CL1 Antibody (Quetmolimab, Research Use) | NBR-0026 |
| Ulocuplumab | CXCR4 | Human CXCR4 Antibody (Ulocuplumab, Research Use) | NBR-0027 |
| MEN1309 | DEC-205 | Human DEC-205 Antibody (MEN1309, Research Use) | NBR-0028 |
| CDX-1401 | DEC-205 | Human DEC-205 Antibody (CDX-1401, Research Use) | NBR-0029 |
| Rovalpituzumab | DLL3 | Human DLL3 Antibody (Rovalpituzumab, Research Use) | NBR-0030 |
| Dragonfly patent anti-DLL3 | DLL3 | Human DLL3 Antibody (Dragonfly patent anti-DLL3, Research Use) | NBR-0031 |
| Conatumumab | DR5 | Human DR5 / TRAILR2 Antibody (Conatumumab, Research Use) | NBR-0032 |
| Tigatuzumab | DR5 / TRAILR2 | Human DR5 / TRAILR2 Antibody (Tigatuzumab, Research Use) | NBR-0033 |
| Cetuximab | EGFR | Human EGFR Antibody (Cetuximab, Research Use) | NBR-0034 |
| MEDI-547 | EphA2 | Human EphA2 Antibody (MEDI-547, Research Use) | NBR-0035 |
| Sanofi Aventis patent anti-EphA2 | EphA2 | Human EphA2 Antibody (Sanofi Aventis patent anti-EphA2, Research Use) | NBR-0036 |
| Rozanolixizumab | FcRn | Human FcRn Antibody (Rozanolixizumab, Research Use) | NBR-0037 |
| Bemarituzumab | FGFR2 | Human FGFR2 Antibody (Bemarituzumab, Research Use) | NBR-0038 |
| Aprutumab | FGFR2 | Human FGFR2 Antibody (Aprutumab, Research Use) | NBR-0039 |
| Farletuzumab | FRA | Human FRA Antibody (Farletuzumab, Research Use) | NBR-0040 |
| Mirvetuximab | FRA | Human FRA Antibody (Mirvetuximab, Research Use) | NBR-0041 |
| Codrituzumab | GPC3 | Human GPC3 Antibody (Codrituzumab, Research Use) | NBR-0042 |
| Disitamab | HER2 | Human HER2 Antibody (Disitamab, Research Use) | NBR-0043 |
| Zanidatamab | HER2 | Human HER2 Antibody (Zanidatamab, Research Use) | NBR-0044 |
| Trastuzumab | HER2 | Human HER2 Antibody (Trastuzumab, Research Use) | NBR-0045 |
| Pertuzumab | HER2 | Human HER2 Antibody (Pertuzumab, Research Use) | NBR-0046 |
| Ordesekimab | IL-15 | Human IL-15 Antibody (Ordesekimab, Research Use) | NBR-0047 |
| Brodalumab | IL-17RA | Human IL-17RA Antibody (Brodalumab, Research Use) | NBR-0048 |
| GSK 1070806 | IL-18 | Human IL-18 Antibody (GSK 1070806, Research Use) | NBR-0049 |
| Nidanilimab | IL-1RAP | Human IL-1RAP Antibody (Nidanilimab, Research Use) | NBR-0050 |
| Lilly patent anti-IL-21 | IL-21 | Human IL-21 Antibody (Lilly patent anti-IL-21, Research Use) | NBR-0051 |
| Clazakizumab | IL-6 | Human IL-6 Antibody (Clazakizumab, Research Use) | NBR-0052 |
| Vobarilizumab | IL-6R | Human IL-6R Antibody (Vobarilizumab, Research Use) | NBR-0053 |
| Sarilumab | IL-6R | Human IL-6R Antibody (Sarilumab, Research Use) | NBR-0054 |
| Tocilizumab | IL-6R | Human IL-6R Antibody (Tocilizumab, Research Use) | NBR-0055 |
| Lirilumab | KIR | Human KIR Antibody (Lirilumab, Research Use) | NBR-0056 |
| Lacutamab | KIR3DL2 | Human KIR3DL2 Antibody (Lacutamab, Research Use) | NBR-0057 |
| MSC-1 | LIF | Human LIF Antibody (MSC-1, Research Use) | NBR-0058 |
| Merck patent anti-ILT3 complex | LILRB4 | Human LILRB4 Antibody (Merck patent anti-ILT3 complex, Research Use) | NBR-0059 |
| U.Texas patent anti-LILRB4 | LILRB4 | Human LILRB4 Antibody (U.Texas patent anti-LILRB4, Research Use) | NBR-0060 |
| Lacnotuzumab | M-CSF | Human M-CSF Antibody (Lacnotuzumab, Research Use) | NBR-0061 |
| Enfortumab | Nectin-4 | Human Nectin-4 Antibody (Enfortumab, Research Use) | NBR-0062 |
| Tesnatilimab | NKG2D | Human NKG2D Antibody (Tesnatilimab, Research Use) | NBR-0063 |
| Oleclumab | NT5E | Human NT5E Antibody (Oleclumab, Research Use) | NBR-0064 |
| Spartalizumab | PD-1 | Human PD-1 Antibody (Spartalizumab, Research Use) | NBR-0065 |
| Camrelizumab | PD-1 | Human PD-1 Antibody (Camrelizumab, Research Use) | NBR-0066 |
| Pembrolizumab | PD-1 | Human PD-1 Antibody (Pembrolizumab, Research Use) | NBR-0067 |
| Nivolumab | PD-1 | Human PD-1 Antibody (Nivolumab, Research Use) | NBR-0068 |
| MOR-8457 | PDGFB | Human PDGFB Antibody (MOR-8457, Research Use) | NBR-0069 |
| Avelumab | PD-L1 | Human PD-L1 Antibody (Avelumab, Research Use) | NBR-0070 |
| MDX-1105 | PD-L1 | Human PD-L1 Antibody (MDX-1105, Research Use) | NBR-0071 |
| Atezolizumab | PD-L1 | Human PD-L1 Antibody (Atezolizumab, Research Use) | NBR-0072 |
| Durvalumab | PD-L1 | Human PD-L1 Antibody (Durvalumab, Research Use) | NBR-0073 |
| Genentech anti-PMEL17 | PMEL17 | Human PMEL17 Antibody (Genentech anti-PMEL17, Research Use) | NBR-0074 |
| Novartis patent anti-PMEL17 | PMEL17 | Human PMEL17 Antibody (Novartis patent anti-PMEL17, Research Use) | NBR-0075 |
| Inclacumab | P-Selectin | Human P-Selectin Antibody (Inclacumab, Research Use) | NBR-0076 |
| Crizanlizumab | P-Selectin | Human P-Selectin Antibody (Crizanlizumab, Research Use) | NBR-0077 |
| Neihulizumab | PSGL1 | Human PSGL1 Antibody (Neihulizumab, Research Use) | NBR-0078 |
| Rosopatamab | PSMA | Human PSMA Antibody (Rosopatamab, Research Use) | NBR-0079 |
| Elezanumab | RGMA | Human RGMA Antibody (Elezanumab, Research Use) | NBR-0080 |
| Zilovertamab | ROR1 | Human ROR1 Antibody (Zilovertamab, Research Use) | NBR-0081 |
| NC318 | Siglec-15 | Human Siglec-15 Antibody (NC318, Research Use) | NBR-0082 |
| Lirentelimab | Siglec-8 | Human Siglec-8 Antibody (Lirentelimab, Research Use) | NBR-0083 |
| Elotuzumab | SLAMF7 | Human SLAMF7 Antibody (Elotuzumab, Research Use) | NBR-0084 |
| Tiragolumab | TIGIT | Human TIGIT Antibody (Tiragolumab, Research Use) | NBR-0085 |
| Adalimumab | TNFa | Human TNFa Antibody (Adalimumab, Research Use) | NBR-0086 |
| Infliximab | TNFa | Human TNFa Antibody (Infliximab, Research Use) | NBR-0087 |
| Bevacizumab | VEGFA | Human VEGFA Antibody (Bevacizumab, Research Use) | NBR-0088 |
| Ramucirumab | KDR / VEGFR2 | Human KDR / VEGFR2 Antibody (Ramucirumab, Research Use) | NBR-0089 |
| Utomilumab | 4-1BB | Human 4-1BB Antibody (Utomilumab, Research Use) | NBR-0090 |
| Urelumab | 4-1BB | Human 4-1BB Antibody (Urelumab, Research Use) | NBR-0091 |
| Abbvie patent anti-TNFSF9 | 4-1BBL | Human 4-1BBL Antibody (Abbvie patent anti-TNFSF9, Research Use) | NBR-0092 |
| DS-6016a | ACVR1 | Human ACVR1 Antibody (DS-6016a, Research Use) | NBR-0093 |
| Ab-14E1 | ACVR2A | Human ACVR2A Antibody (Ab-14E1, Research Use) | NBR-0094 |
| Bimagrumab | ACVR2B | Human ACVR2B Antibody (Bimagrumab, Research Use) | NBR-0095 |
| Praluzatamab | ALCAM | Human ALCAM Antibody (Praluzatamab, Research Use) | NBR-0096 |
| AT002 | ALCAM | Human ALCAM Antibody (AT002, Research Use) | NBR-0097 |
| Ascrinvacumab | ALK-1 | Human ALK-1 Antibody (Ascrinvacumab, Research Use) | NBR-0098 |
| Cinpanemab | Alpha-synuclein | Human Alpha-synuclein Antibody (Cinpanemab, Research Use) | NBR-0099 |
| Prasinezumab | Alpha-synuclein | Human Alpha-synuclein Antibody (Prasinezumab, Research Use) | NBR-0100 |
| Nesvacumab | Angiopoietin-2 | Human Angiopoietin-2 Antibody (Nesvacumab, Research Use) | NBR-0101 |
| Evinacumab | Angiopoietin-like3 | Human Angiopoietin-like3 Antibody (Evinacumab, Research Use) | NBR-0102 |
| Dezamizumab | APCS | Human APCS Antibody (Dezamizumab, Research Use) | NBR-0103 |
| BION-1301 | APRIL | Human APRIL Antibody (BION-1301, Research Use) | NBR-0104 |
| Enoblituzumab | B7-H3 | Human B7-H3 Antibody (Enoblituzumab, Research Use) | NBR-0105 |
| Onvatilimab | B7-H5 / VISTA | Human B7-H5 / VISTA Antibody (Onvatilimab, Research Use) | NBR-0106 |
| Dartmouth patent anti-B7-H6 | B7-H6 | Human B7-H6 Antibody (Dartmouth patent anti-B7-H6, Research Use) | NBR-0107 |
| Belimumab | BAFF | Human BAFF Antibody (Belimumab, Research Use) | NBR-0108 |
| U.Toronto patent anti-Bax | Bcl-2 | Human Bcl-2 Antibody (U.Toronto patent anti-Bax, Research Use) | NBR-0109 |
| RG7992 | Beta-Klotho | Human Beta-Klotho Antibody (RG7992, Research Use) | NBR-0110 |
| NGM313 | Beta-Klotho | Human Beta-Klotho Antibody (NGM313, Research Use) | NBR-0111 |
| XmAb 5592 | BST2 | Human BST2 Antibody (XmAb 5592, Research Use) | NBR-0112 |
| Sutimlimab | C1s | Human C1s Antibody (Sutimlimab, Research Use) | NBR-0113 |
| G2_anti-C5aR | C5aR | Human C5aR Antibody (G2_anti-C5aR, Research Use) | NBR-0114 |
| HKT288+D116 | Cadherin-6 | Human Cadherin-6 Antibody (HKT288+D116, Research Use) | NBR-0115 |
| Girentuximab | CAIX | Human CAIX Antibody (Girentuximab, Research Use) | NBR-0116 |
| Fsn0503h | Cathepsin S | Human Cathepsin S Antibody (Fsn0503h, Research Use) | NBR-0117 |
| VLST-002 | CCL5 | Human CCL5 Antibody (VLST-002, Research Use) | NBR-0118 |
| Plozalizumab | CCR2 | Human CCR2 Antibody (Plozalizumab, Research Use) | NBR-0119 |
| Mogamulizumab | CCR4 | Human CCR4 Antibody (Mogamulizumab, Research Use) | NBR-0120 |
| R707 | CCR7 | Human CCR7 Antibody (R707, Research Use) | NBR-0121 |
| LOP628 | CD117 | Human CD117 Antibody (LOP628, Research Use) | NBR-0122 |
| SNG-CD123A | IL-3RA | Human IL-3RA Antibody (SNG-CD123A, Research Use) | NBR-0123 |
| Talacotuzumab | IL-3RA | Human IL-3RA Antibody (Talacotuzumab, Research Use) | NBR-0124 |
| Forerunner patent anti-Prominin-1 | CD133 | Human CD133 Antibody (Forerunner patent anti-Prominin-1, Research Use) | NBR-0125 |
| Samalizumab | CD200 | Human CD200 Antibody (Samalizumab, Research Use) | NBR-0126 |
| Janssen patent anti-CD200R1 | CD200R | Human CD200R Antibody (Janssen patent anti-CD200R1, Research Use) | NBR-0127 |
| Basiliximab | CD25 / IL-1RA | Human CD25 / IL-1RA Antibody (Basiliximab, Research Use) | NBR-0128 |
| Belantamab | BCMA | Human BCMA Antibody (Belantamab, Research Use) | NBR-0129 |
| VIB9600 | CD32a | Human CD32a Antibody (VIB9600, Research Use) | NBR-0130 |
| TTX-030 | CD39 | Human CD39 Antibody (TTX-030, Research Use) | NBR-0131 |
| Bleselumab | CD40 | Human CD40 Antibody (Bleselumab, Research Use) | NBR-0132 |
| Sotigalimab | CD40 | Human CD40 Antibody (Sotigalimab, Research Use) | NBR-0133 |
| Dacetuzumab | CD40 | Human CD40 Antibody (Dacetuzumab, Research Use) | NBR-0134 |
| FOR46 | CD46 | Human CD46 Antibody (FOR46, Research Use) | NBR-0135 |
| Magrolimab | CD47 | Human CD47 Antibody (Magrolimab, Research Use) | NBR-0136 |
| CC-90002 | CD47 | Human CD47 Antibody (CC-90002, Research Use) | NBR-0137 |
| Alemtuzumab | CD52 | Human CD52 Antibody (Alemtuzumab, Research Use) | NBR-0138 |
| Lorvotuzumab | CD56 | Human CD56 Antibody (Lorvotuzumab, Research Use) | NBR-0139 |
| Genefrontier patent anti-CD69 | CD69 | Human CD69 Antibody (Genefrontier patent anti-CD69, Research Use) | NBR-0140 |
| Polatuzumab | CD79b / Ig B | Human CD79b / Ig B Antibody (Polatuzumab, Research Use) | NBR-0141 |
| U.California patent anti-CDCP1 | CDCP1 | Human CDCP1 Antibody (U.California patent anti-CDCP1, Research Use) | NBR-0142 |
| Labetuzumab | CEA | Human CEA Antibody (Labetuzumab, Research Use) | NBR-0143 |
| CM-24 | CEACAM1 | Human CEACAM1 Antibody (CM-24, Research Use) | NBR-0144 |
| NEO-201 | CEACAM6 | Human CEACAM6 Antibody (NEO-201, Research Use) | NBR-0145 |
| Brown U. patent anti-CHI3L1 | Chitinase3-like1 | Human Chitinase3-like1 Antibody (Brown U. patent anti-CHI3L1, Research Use) | NBR-0146 |
| GSK3050002 | CK-B4 | Human CK-B4 Antibody (GSK3050002, Research Use) | NBR-0147 |
| FA19-1 | CLCP1 | Human CLCP1 Antibody (FA19-1, Research Use) | NBR-0148 |
| Zolbetuximab | CLDN18 | Human CLDN18 Antibody (Zolbetuximab, Research Use) | NBR-0149 |
| IMAB027 | CLDN6 | Human CLDN6 Antibody (IMAB027, Research Use) | NBR-0150 |
| Tepoditamab | CLEC12A | Human CLEC12A Antibody (Tepoditamab, Research Use) | NBR-0151 |
| Scripps Korea patent anti-CLEC14A | CLEC14A | Human CLEC14A Antibody (Scripps Korea patent anti-CLEC14A, Research Use) | NBR-0152 |
| Oxford Bio patent anti-CRTAM | CRTAM | Human CRTAM Antibody (Oxford Bio patent anti-CRTAM, Research Use) | NBR-0153 |
| Cabiralizumab | CSF1R | Human CSF1R Antibody (Cabiralizumab, Research Use) | NBR-0154 |
| Med. Bio. Labs patent anti-CXADR | CXADR | Human CXADR Antibody (Med. Bio. Labs patent anti-CXADR, Research Use) | NBR-0155 |
| Eldelumab | CXCL10 | Human CXCL10 Antibody (Eldelumab, Research Use) | NBR-0156 |
| Novimmune patent anti-CXCL9 | CXCL9 | Human CXCL9 Antibody (Novimmune patent anti-CXCL9, Research Use) | NBR-0157 |
| SAR113244 | CXCR5 | Human CXCR5 Antibody (SAR113244, Research Use) | NBR-0158 |
| INSERM patent anti-DC-SIGN | DC-SIGN | Human DC-SIGN Antibody (INSERM patent anti-DC-SIGN, Research Use) | NBR-0159 |
| Baylor patent anti-Dectin-1 | Dectin-1 | Human Dectin-1 Antibody (Baylor patent anti-Dectin-1, Research Use) | NBR-0160 |
| BHQ-880 | DKK1 | Human DKK1 Antibody (BHQ-880, Research Use) | NBR-0161 |
| Demcizumab | DLL4 | Human DLL4 Antibody (Demcizumab, Research Use) | NBR-0162 |
| Navicixizumab | DLL4 | Human DLL4 Antibody (Navicixizumab, Research Use) | NBR-0163 |
| Abbvie patent anti-TNFRSF21 | DR6 | Human DR6 Antibody (Abbvie patent anti-TNFRSF21, Research Use) | NBR-0164 |
| Citatuzumab | EPCAM | Human EPCAM Antibody (Citatuzumab, Research Use) | NBR-0165 |
| Genentech patent anti-EphB2 | EphB2 | Human EphB2 Antibody (Genentech patent anti-EphB2, Research Use) | NBR-0166 |
| Morphosys patent anti-EphB4 | EphB4 | Human EphB4 Antibody (Morphosys patent anti-EphB4, Research Use) | NBR-0167 |
| VasGene patent anti-EphB4 | EphB4 | Human EphB4 Antibody (VasGene patent anti-EphB4, Research Use) | NBR-0168 |
| Roche patent anti-Her3 / Her4 | ErbB4 | Human ErbB4 Antibody (Roche patent anti-Her3 / Her4, Research Use) | NBR-0169 |
| Abbott patent anti-EPO Receptor | ErythropoietinR | Human ErythropoietinR Antibody (Abbott patent anti-EPO Receptor, Research Use) | NBR-0170 |
| Sibrotuzumab | FAP | Human FAP Antibody (Sibrotuzumab, Research Use) | NBR-0171 |
| LY2928057 | Ferroportin | Human Ferroportin Antibody (LY2928057, Research Use) | NBR-0172 |
| Amgen patent anti-Ferroportin | Ferroportin | Human Ferroportin Antibody (Amgen patent anti-Ferroportin, Research Use) | NBR-0173 |
| 1A6 | FGF19 | Human FGF19 Antibody (1A6, Research Use) | NBR-0174 |
| HuGAL-F2 | FGF2 | Human FGF2 Antibody (HuGAL-F2, Research Use) | NBR-0175 |
| LY3076226 | FGFR3 | Human FGFR3 Antibody (LY3076226, Research Use) | NBR-0176 |
| Vofatamab | FGFR3 | Human FGFR3 Antibody (Vofatamab, Research Use) | NBR-0177 |
| U3-1784 | FGFR4 | Human FGFR4 Antibody (U3-1784, Research Use) | NBR-0178 |
| L19-TNF | Fibronectin | Human Fibronectin Antibody (L19-TNF, Research Use) | NBR-0179 |
| IMC-EB10 | FLT3 | Human FLT3 Antibody (IMC-EB10, Research Use) | NBR-0180 |
| U.Toronto patent anti-FZD7 | Frizzled-7 | Human Frizzled-7 Antibody (U.Toronto patent anti-FZD7, Research Use) | NBR-0181 |
| Crotedumab | GCGR | Human GCGR Antibody (Crotedumab, Research Use) | NBR-0182 |
| Volagidemab | GCGR | Human GCGR Antibody (Volagidemab, Research Use) | NBR-0183 |
| CSL patent anti-G-CSFR | G-CSFR | Human G-CSFR Antibody (CSL patent anti-G-CSFR, Research Use) | NBR-0184 |
| Amgen patent anti-GIPR | GIPR | Human GIPR Antibody (Amgen patent anti-GIPR, Research Use) | NBR-0185 |
| Ragifilimab | GITR | Human GITR Antibody (Ragifilimab, Research Use) | NBR-0186 |
| Mavrilimumab | GM-CSF2RA | Human GM-CSF2RA Antibody (Mavrilimumab, Research Use) | NBR-0187 |
| Regeneron patent anti-GP130 / LEPR | Gp130 | Human Gp130 Antibody (Regeneron patent anti-GP130 / LEPR, Research Use) | NBR-0188 |
| KRN330 | GPA33 | Human GPA33 Antibody (KRN330, Research Use) | NBR-0189 |
| Glembatumumab | GPNMB | Human GPNMB Antibody (Glembatumumab, Research Use) | NBR-0190 |
| BNC101 | GPR49 | Human GPR49 Antibody (BNC101, Research Use) | NBR-0191 |
| Petosemtamab | GPR49 | Human GPR49 Antibody (Petosemtamab, Research Use) | NBR-0192 |
| Talquetamab | GPRC5D | Human GPRC5D Antibody (Talquetamab, Research Use) | NBR-0193 |
| UCB patent anti-Gremlin-1 | Gremlin | Human Gremlin Antibody (UCB patent anti-Gremlin-1, Research Use) | NBR-0194 |
| KHK patent anti-Haptoglobin | Haptoglobin | Human Haptoglobin Antibody (KHK patent anti-Haptoglobin, Research Use) | NBR-0195 |
| KHK2866 | HB-EGF | Human HB-EGF Antibody (KHK2866, Research Use) | NBR-0196 |
| U3-1565 | HB-EGF | Human HB-EGF Antibody (U3-1565, Research Use) | NBR-0197 |
| Patritumab | HER3 | Human HER3 Antibody (Patritumab, Research Use) | NBR-0198 |
| Seribantumab | HER3 | Human HER3 Antibody (Seribantumab, Research Use) | NBR-0199 |
| Ficlatuzumab | HGF / SF | Human HGF / SF Antibody (Ficlatuzumab, Research Use) | NBR-0200 |
| Rilotumumab | HGF / SF | Human HGF / SF Antibody (Rilotumumab, Research Use) | NBR-0201 |
| Emibetuzumab | c-Met / HGFR | Human c-Met / HGFR Antibody (Emibetuzumab, Research Use) | NBR-0202 |
| Vopratelimab | ICOS | Human ICOS Antibody (Vopratelimab, Research Use) | NBR-0203 |
| Feladilimab | ICOS | Human ICOS Antibody (Feladilimab, Research Use) | NBR-0204 |
| LIMR patent anti-IDO2 | IDO2 | Human IDO2 Antibody (LIMR patent anti-IDO2, Research Use) | NBR-0205 |
| Rontalizumab | IFNA1 | Human IFNA1 Antibody (Rontalizumab, Research Use) | NBR-0206 |
| Sifalimumab | IFNA1 | Human IFNA1 Antibody (Sifalimumab, Research Use) | NBR-0207 |
| Xentuzumab | IGF-1 | Human IGF-1 Antibody (Xentuzumab, Research Use) | NBR-0208 |
| Teprotumumab | IGF-1R | Human IGF-1R Antibody (Teprotumumab, Research Use) | NBR-0209 |
| Ustekinumab | IL-12 | Human IL-12 Antibody (Ustekinumab, Research Use) | NBR-0210 |
| Anrukinzumab | IL-13 | Human IL-13 Antibody (Anrukinzumab, Research Use) | NBR-0211 |
| Wake Forest U. patent anti-IL-13RA2 | IL-13RA2 | Human IL-13RA2 Antibody (Wake Forest U. patent anti-IL-13RA2, Research Use) | NBR-0212 |
| MOR106 | IL-17C | Human IL-17C Antibody (MOR106, Research Use) | NBR-0213 |
| AMG 108 | IL-1R1 | Human IL-1R1 Antibody (AMG 108, Research Use) | NBR-0214 |
| Spesolimab | IL-1RL2 | Human IL-1RL2 Antibody (Spesolimab, Research Use) | NBR-0215 |
| Imsidolimab | IL-1RL2 | Human IL-1RL2 Antibody (Imsidolimab, Research Use) | NBR-0216 |
| Fletikumab | IL-20 | Human IL-20 Antibody (Fletikumab, Research Use) | NBR-0217 |
| Cheng Kung U. patent anti-IL-20R1 | IL-20RA | Human IL-20RA Antibody (Cheng Kung U. patent anti-IL-20R1, Research Use) | NBR-0218 |
| Fezakinumab | IL-22 | Human IL-22 Antibody (Fezakinumab, Research Use) | NBR-0219 |
| Guselkumab | IL-23 | Human IL-23 Antibody (Guselkumab, Research Use) | NBR-0220 |
| Tildrakizumab | IL-23P19 | Human IL-23P19 Antibody (Tildrakizumab, Research Use) | NBR-0221 |
| Singapore ASTR patent anti-IL-2R beta / IL-2R gamma | IL-2RB | Human IL-2RB Antibody (Singapore ASTR patent anti-IL-2R beta / IL-2R gamma , Research Use) | NBR-0222 |
| Daclizumab | IL-2RA | Human IL-2RA Antibody (Daclizumab, Research Use) | NBR-0223 |
| Nemolizumab | IL-31RA | Human IL-31RA Antibody (Nemolizumab, Research Use) | NBR-0224 |
| Etokimab | IL-33 | Human IL-33 Antibody (Etokimab, Research Use) | NBR-0225 |
| Pascolizumab | IL-4 | Human IL-4 Antibody (Pascolizumab, Research Use) | NBR-0226 |
| Dupilumab | IL-4RA | Human IL-4RA Antibody (Dupilumab, Research Use) | NBR-0227 |
| Mepolizumab | IL-5 | Human IL-5 Antibody (Mepolizumab, Research Use) | NBR-0228 |
| Benralizumab | IL-5RA | Human IL-5RA Antibody (Benralizumab, Research Use) | NBR-0229 |
| Lusvertikimab | IL-7RA | Human IL-7RA Antibody (Lusvertikimab, Research Use) | NBR-0230 |
| HuMax-IL8 | IL-8 | Human IL-8 Antibody (HuMax-IL8, Research Use) | NBR-0231 |
| Enokizumab | IL-9 | Human IL-9 Antibody (Enokizumab , Research Use) | NBR-0232 |
| Innate patent anti-KIR2DL | KIR2DL1 | Human KIR2DL1 Antibody (Innate patent anti-KIR2DL , Research Use) | NBR-0233 |
| Relatlimab | LAG3 | Human LAG3 Antibody (Relatlimab, Research Use) | NBR-0234 |
| Brigham and Womens anti-LAP | LAP | Human LAP Antibody (Brigham and Womens anti-LAP, Research Use) | NBR-0235 |
| Mibavademab | LEPR | Human LEPR Antibody (Mibavademab, Research Use) | NBR-0236 |
| MB 311 | LeY | Human LeY Antibody (MB 311, Research Use) | NBR-0237 |
| JTX-8064 | LILRB2 | Human LILRB2 Antibody (JTX-8064, Research Use) | NBR-0238 |
| Simtuzumab | LOXL2 | Human LOXL2 Antibody (Simtuzumab, Research Use) | NBR-0239 |
| Ontamalimab | MAdCAM-1 | Human MAdCAM-1 Antibody (Ontamalimab, Research Use) | NBR-0240 |
| Refanezumab | MAG | Human MAG Antibody (Refanezumab, Research Use) | NBR-0241 |
| CT Atlantic patent anti-MAGE-A3 | MAGE-A3 | Human MAGE-A3 Antibody (CT Atlantic patent anti-MAGE-A3, Research Use) | NBR-0242 |
| Narsoplimab | MASP-2 | Human MASP-2 Antibody (Narsoplimab, Research Use) | NBR-0243 |
| RGX-019 | MERTK | Human MERTK Antibody (RGX-019, Research Use) | NBR-0244 |
| Amatuximab | Mesothelin | Human Mesothelin Antibody (Amatuximab, Research Use) | NBR-0245 |
| Anetumab | Mesothelin | Human Mesothelin Antibody (Anetumab, Research Use) | NBR-0246 |
| Imalumab | MIF | Human MIF Antibody (Imalumab, Research Use) | NBR-0247 |
| Andecaliximab | MMP-9 | Human MMP-9 Antibody (Andecaliximab, Research Use) | NBR-0248 |
| Ensituximab | MU5AC | Human MU5AC Antibody (Ensituximab, Research Use) | NBR-0249 |
| Clivatuzumab | MUC1 | Human MUC1 Antibody (Clivatuzumab, Research Use) | NBR-0250 |
| Oregovomab | MUC16 | Human MUC16 Antibody (Oregovomab, Research Use) | NBR-0251 |
| Sofituzumab | CA125 | Human CA125 Antibody (Sofituzumab, Research Use) | NBR-0252 |
| Landogrozumab | Myostatin | Human Myostatin Antibody (Landogrozumab, Research Use) | NBR-0253 |
| Trevogrumab | Myostatin | Human Myostatin Antibody (Trevogrumab, Research Use) | NBR-0254 |
| Fulranumab | NGF | Human NGF Antibody (Fulranumab, Research Use) | NBR-0255 |
| Tanezumab | NGF | Human NGF Antibody (Tanezumab, Research Use) | NBR-0256 |
| Monalizumab | NKG2A | Human NKG2A Antibody (Monalizumab, Research Use) | NBR-0257 |
| Ozanezumab | Nogo-A | Human Nogo-A Antibody (Ozanezumab, Research Use) | NBR-0258 |
| Brontictuzumab | Notch1 | Human Notch1 Antibody (Brontictuzumab, Research Use) | NBR-0259 |
| Vesencumab | NRP1 | Human NRP1 Antibody (Vesencumab, Research Use) | NBR-0260 |
| Tavolixizumab | OX40 | Human OX40 Antibody (Tavolixizumab, Research Use) | NBR-0261 |
| Oxelumab | OX40L | Human OX40L Antibody (Oxelumab, Research Use) | NBR-0262 |
| Alirocumab | PCSK9 | Human PCSK9 Antibody (Alirocumab, Research Use) | NBR-0263 |
| Thrombogenics patent anti-PDGF-C | PDGFC | Human PDGFC Antibody (Thrombogenics patent anti-PDGF-C, Research Use) | NBR-0264 |
| Tovetumab | PDGFRA | Human PDGFRA Antibody (Tovetumab, Research Use) | NBR-0265 |
| Olaratumab | PDGFRA | Human PDGFRA Antibody (Olaratumab, Research Use) | NBR-0266 |
| Rinucumab | PDGFRB | Human PDGFRB Antibody (Rinucumab, Research Use) | NBR-0267 |
| Novo Nordisk patent anti-PGLYRP1 | PGLYRP1 | Human PGLYRP1 Antibody (Novo Nordisk patent anti-PGLYRP1, Research Use) | NBR-0268 |
| Diaccurate patent anti-sPLA2-GIB | PLA2G1B | Human PLA2G1B Antibody (Diaccurate patent anti-sPLA2-GIB, Research Use) | NBR-0269 |
| Eureka patent anti-PRAME | PRAME | Human PRAME Antibody (Eureka patent anti-PRAME, Research Use) | NBR-0270 |
| AGS-1C4D4 | PSCA | Human PSCA Antibody (AGS-1C4D4, Research Use) | NBR-0271 |
| GSK4381562 | PVRIG | Human PVRIG Antibody (GSK4381562, Research Use) | NBR-0272 |
| COM701 | PVRIG | Human PVRIG Antibody (COM701, Research Use) | NBR-0273 |
| XT-M4 | RAGE | Human RAGE Antibody (XT-M4, Research Use) | NBR-0274 |
| Denosumab | RANKL | Human RANKL Antibody (Denosumab, Research Use) | NBR-0275 |
| Narnatumab | RON | Human RON Antibody (Narnatumab, Research Use) | NBR-0276 |
| Oncomed patent anti-RSPO1 | RSPO1 | Human RSPO1 Antibody (Oncomed patent anti-RSPO1, Research Use) | NBR-0277 |
| Rosmantuzumab | RSPO3 | Human RSPO3 Antibody (Rosmantuzumab, Research Use) | NBR-0278 |
| Setrusumab | Sclerostin | Human Sclerostin Antibody (Setrusumab, Research Use) | NBR-0279 |
| Romosozumab | Sclerostin | Human Sclerostin Antibody (Romosozumab, Research Use) | NBR-0280 |
| Pepinemab | SEMA4D | Human SEMA4D Antibody (Pepinemab, Research Use) | NBR-0281 |
| Hospital for Sick Children patent anti-SIRPA | SIRPA | Human SIRPA Antibody (Hospital for Sick Children patent anti-SIRPA, Research Use) | NBR-0282 |
| KWAR23 | SIRPG | Human SIRPG Antibody (KWAR23, Research Use) | NBR-0283 |
| Bexmarilimab | STAB1 | Human STAB1 Antibody (Bexmarilimab, Research Use) | NBR-0284 |
| Vandortuzumab | STEAP1 | Human STEAP1 Antibody (Vandortuzumab, Research Use) | NBR-0285 |
| Indatuximab | Syndecan-1 | Human Syndecan-1 Antibody (Indatuximab, Research Use) | NBR-0286 |
| Gosuranemab | Tau | Human Tau Antibody (Gosuranemab, Research Use) | NBR-0287 |
| Semorinemab | Tau | Human Tau Antibody (Semorinemab, Research Use) | NBR-0288 |
| Tisotumab | TF | Human TF Antibody (Tisotumab, Research Use) | NBR-0289 |
| SRK181 | TGFb | Human TGFb Antibody (SRK181, Research Use) | NBR-0290 |
| M7824 | TGFb | Human TGFb Antibody (M7824, Research Use) | NBR-0291 |
| Sabatolimab | TIM-3 / HAVCR2 | Human TIM-3 / HAVCR2 Antibody (Sabatolimab, Research Use) | NBR-0292 |
| Tomaralimab | TLR2 | Human TLR2 Antibody (Tomaralimab, Research Use) | NBR-0293 |
| C1068 | TLR3 | Human TLR3 Antibody (C1068, Research Use) | NBR-0294 |
| Mapatumumab | TRAIL-R1 | Human TRAIL-R1 Antibody (Mapatumumab, Research Use) | NBR-0295 |
| GBR 900 | TrkA | Human TrkA Antibody (GBR 900, Research Use) | NBR-0296 |
| Sacituzumab | TROP-2 | Human TROP-2 Antibody (Sacituzumab, Research Use) | NBR-0297 |
| Enavatuzumab | TWEAKR | Human TWEAKR Antibody (Enavatuzumab, Research Use) | NBR-0298 |
| ELB031 | TYRO3 | Human TYRO3 Antibody (ELB031, Research Use) | NBR-0299 |
| Timolumab | VAP-1 | Human VAP-1 Antibody (Timolumab, Research Use) | NBR-0300 |
| Icrucumab | FLT1 / VEGFR1 | Human FLT1 / VEGFR1 Antibody (Icrucumab, Research Use) | NBR-0301 |
| DS-6000a | CDH6 | Human CDH6 Antibody (DS-6000a, Research Use) | NBR-0302 |
| Tabituximab | Frizzled-10 | Human Frizzled-10 Antibody (Tabituximab, Research Use) | NBR-0303 |
| Itolizumab | CD6 | Human CD6 Antibody (Itolizumab, Research Use) | NBR-0304 |
| Asclepius Technology patent anti-Robo1 CAR | Robo1 | Human Robo1 Antibody (Asclepius Technology patent anti-Robo1 CAR, Research Use) | NBR-0305 |
| Murlentamab | AMHR2 | Human AMHR2 Antibody (Murlentamab, Research Use) | NBR-0306 |
| Idactamab | ASCT2 | Human ASCT2 Antibody (Idactamab, Research Use) | NBR-0307 |
| Carotuximab | CD105 | Human CD105 Antibody (Carotuximab, Research Use) | NBR-0308 |
| Regeneron patent anti-CD48 | CD48 | Human CD48 Antibody (Regeneron patent anti-CD48, Research Use) | NBR-0309 |
| SC-005 | Melanotransferrin | Human Melanotransferrin Antibody (SC-005, Research Use) | NBR-0310 |
| Ianalumab | BAFFR | Human BAFFR Antibody (Ianalumab, Research Use) | NBR-0311 |
| GFB-024 | CB1 | Human CB1 Antibody (GFB-024, Research Use) | NBR-0312 |
| Erenumab | CGRPR | Human CGRPR Antibody (Erenumab, Research Use) | NBR-0313 |
| Garadacimab | Factor XII | Human Factor XII Antibody (Garadacimab, Research Use) | NBR-0314 |
| Burosumab | FGF23 | Human FGF23 Antibody (Burosumab, Research Use) | NBR-0315 |
| BMS-986012 | Fucosyl GM1 | Human Fucosyl GM1 Antibody (BMS-986012, Research Use) | NBR-0316 |
| Anifrolumab | IFNAR-1 | Human IFNAR-1 Antibody (Anifrolumab, Research Use) | NBR-0317 |
| ARGX-112 | IL-22RA | Human IL-22RA Antibody (ARGX-112, Research Use) | NBR-0318 |
| Daxdilimab | ILT7 | Human ILT7 Antibody (Daxdilimab, Research Use) | NBR-0319 |
| Lanadelumab | Kallikrein | Human Kallikrein Antibody (Lanadelumab, Research Use) | NBR-0320 |
| Orticumab | oxLDL | Human oxLDL Antibody ( Orticumab, Research Use) | NBR-0321 |
| CTX-2026 | Butyrophilin | Human Butyrophilin Antibody (CTX-2026, Research Use) | NBR-0322 |
| ARGX-117 | C2 | Human C2 Antibody (ARGX-117, Research Use) | NBR-0323 |
| NGM621 | C3 | Human C3 Antibody (NGM621, Research Use) | NBR-0324 |
| Atibuclimab | CD14 | Human CD14 Antibody (Atibuclimab, Research Use) | NBR-0325 |
| AB-16B5 | Clusterin | Human Clusterin Antibody (AB-16B5, Research Use) | NBR-0326 |
| CSL324 | G-CSF | Human G-CSF Antibody (CSL324, Research Use) | NBR-0327 |
| DS-6157 | GPR20 | Human GPR20 Antibody (DS-6157, Research Use) | NBR-0328 |
| OS2966 | Integrin B1 | Human Integrin B1 Antibody (OS2966, Research Use) | NBR-0329 |
| NP137 | Netrin 1 | Human Netrin 1 Antibody (NP137, Research Use) | NBR-0330 |
| Bavituximab | Phosphatidylserine | Human Phosphatidylserine Antibody ( Bavituximab, Research Use) | NBR-0331 |
| CSL346 | VEGFB | Human VEGFB Antibody (CSL346, Research Use) | NBR-0332 |
| Garetosmab | Activin A | Human Activin A Antibody (Garetosmab, Research Use) | NBR-0333 |
| Enibarcimab | Adrenomedullin | Human Adrenomedullin Antibody (Enibarcimab, Research Use) | NBR-0334 |
| ANX005 | C1q | Human C1q Antibody (ANX005, Research Use) | NBR-0335 |
| CSL311 | CSF2RB | Human CSF2RB Antibody (CSL311, Research Use) | NBR-0336 |
| NGM120 | GFRAL | Human GFRAL Antibody (NGM120, Research Use) | NBR-0337 |
| Glenzocimab | GPVI | Human GPVI Antibody (Glenzocimab, Research Use) | NBR-0338 |
| ATH3G10 | Phosphorylcholine | Human Phosphorylcholine Antibody (ATH3G10, Research Use) | NBR-0339 |
| M6495 | ADAMTS5 | Human ADAMTS5 Antibody (M6495, Research Use) | NBR-0340 |
| MK-6105 | IL-13RA1 | Human IL-13RA1 Antibody (MK-6105, Research Use) | NBR-0341 |
| Bapotulimab | ILDR2 | Human ILDR2 Antibody (Bapotulimab, Research Use) | NBR-0342 |
| Indusatumab | GCC | Human GCC Antibody (Indusatumab, Research Use) | NBR-0343 |
| STX-100 | Integrin AV & B6 | Human Integrin AV & B6 Antibody (STX-100, Research Use) | NBR-0344 |
| Milatuzumab | MHC | Human MHC Antibody (Milatuzumab, Research Use) | NBR-0345 |
| Lifastuzumab | NaPi2b | Human NaPi2b Antibody ( Lifastuzumab, Research Use) | NBR-0346 |
| MGD007 | A33 | Human A33 Antibody (MGD007, Research Use) | NBR-0347 |
| Apamistamab | CD45 | Human CD45 Antibody (Apamistamab, Research Use) | NBR-0348 |
| Emicizumab | Factor IX | Human Factor IX Antibody (Emicizumab, Research Use) | NBR-0349 |
| Vedolizumab | Integrin A4 & B7 | Human Integrin A4 & B7 Antibody ( Vedolizumab, Research Use) | NBR-0350 |
| MVT-5873 | Sialyl-Lewis A | Human Sialyl-Lewis A Antibody (MVT-5873, Research Use) | NBR-0351 |
| INSERM patent anti-vWF | vWF | Human vWF Antibody (INSERM patent anti-vWF, Research Use) | NBR-0352 |
| Genzyme patent anti-CXCR3 | CXCR3 | Human CXCR3 Antibody (Genzyme patent anti-CXCR3, Research Use) | NBR-0353 |
| TA136 | TPOR | Human TPOR Antibody (TA136, Research Use) | NBR-0354 |
| Genentech patent anti-Tryptase Beta 1 | TPSAB1 | Human TPSAB1 Antibody (Genentech patent anti-Tryptase Beta 1, Research Use) | NBR-0355 |
| Genentech patent anti-Bv8 | Bv8 | Human Bv8 Antibody (Genentech patent anti-Bv8, Research Use) | NBR-0356 |
| M116 | CCL17 | Human CCL17 Antibody (M116, Research Use) | NBR-0357 |
| KHK patent anti-CRTH2 | CRTh2 | Human CRTh2 Antibody (KHK patent anti-CRTH2, Research Use) | NBR-0358 |
| Cureab patent anti-GP73 | GP73 | Human GP73 Antibody (Cureab patent anti-GP73, Research Use) | NBR-0359 |
| Regeneron patent anti-GREM1 | GREM1 | Human GREM1 Antibody (Regeneron patent anti-GREM1, Research Use) | NBR-0360 |
| Erlizumab | Integrin B2 | Human Integrin B2 Antibody (Erlizumab, Research Use) | NBR-0361 |
| Abbott patent anti-NGR | NGR | Human NGR Antibody (Abbott patent anti-NGR, Research Use) | NBR-0362 |
| Lilly patent anti-PACAP | PACAP-38 | Human PACAP-38 Antibody (Lilly patent anti-PACAP, Research Use) | NBR-0363 |
| Novelmed patent anti-Properdin | Properdin | Human Properdin Antibody (Novelmed patent anti-Properdin, Research Use) | NBR-0364 |
| DISC-0974 | RGM C | Human RGM C Antibody (DISC-0974, Research Use) | NBR-0365 |
| Genentech patent anti-TAT226 | TAT226 | Human TAT226 Antibody (Genentech patent anti-TAT226, Research Use) | NBR-0366 |
| Regeneron patent anti-TMPRSS2 | TMPRSS2 | Human TMPRSS2 Antibody (Regeneron patent anti-TMPRSS2 , Research Use) | NBR-0367 |
| Genentech patent anti-HGFA | HGFA | Human HGFA Antibody (Genentech patent anti-HGFA , Research Use) | NBR-0368 |
| Chugai patent anti-HLA-DQ2 | HLA-DQ2 | Human HLA-DQ2 Antibody (Chugai patent anti-HLA-DQ2, Research Use) | NBR-0369 |
| Genentech patent anti-KLK5 | KLK5 | Human KLK5 Antibody (Genentech patent anti-KLK5, Research Use) | NBR-0370 |
| Amgen patent anti-ORAI1 | ORAI1 | Human ORAI1 Antibody (Amgen patent anti-ORAI1, Research Use) | NBR-0371 |
| Sanofi patent anti-PAI-1 | PAI-1 | Human PAI-1 Antibody (Sanofi patent anti-PAI-1, Research Use) | NBR-0372 |
| Novartis patent anti-PAR1 | PAR1 | Human PAR1 Antibody (Novartis patent anti-PAR1, Research Use) | NBR-0373 |
| U.Penn. patent anti-PF4 | PF4 / CXCL4 | Human PF4 / CXCL4 Antibody (U.Penn. patent anti-PF4, Research Use) | NBR-0374 |
| Multiple seq-one in animal | PROKR1 | Human PROKR1 Antibody (Multiple seq-one in animal, Research Use) | NBR-0375 |
| Numab patent anti-HSA | Serum Albumin | Human Serum Albumin Antibody (Numab patent anti-HSA, Research Use) | NBR-0376 |
| Genentech patent anti-STOP-1 | STOP-1 | Human STOP-1 Antibody (Genentech patent anti-STOP-1, Research Use) | NBR-0377 |
| Janssen patent anti-TMEFF2 | TENB2 | Human TENB2 Antibody (Janssen patent anti-TMEFF2, Research Use) | NBR-0378 |
| Regeneron patent anti-TIE-2 | TIE-2 | Human TIE-2 Antibody (Regeneron patent anti-TIE-2, Research Use) | NBR-0379 |
| Novartis patent anti-TMEM16A | TMEM16A | Human TMEM16A Antibody (Novartis patent anti-TMEM16A , Research Use) | NBR-0380 |
| Genentech patent anti-Polyubiquitin | Polyubiquitin | Human Polyubiquitin Antibody (Genentech patent anti-Polyubiquitin, Research Use) | NBR-0381 |
| Duke anti-NAv1.7 | Nav1.7 | Human Nav1.7 Antibody (Duke anti-NAv1.7, Research Use) | NBR-0382 |
| Genentech patent anti-Integrin β7 | Integrin B7 | Human Integrin B7 Antibody (Genentech patent anti-Integrin β7, Research Use) | NBR-0383 |
| Genentech patent anti-Jagged1 | JAG1 | Human JAG1 Antibody (Genentech patent anti-Jagged1, Research Use) | NBR-0384 |
| Regeneron patent anti-APLNR | APLNR | Human APLNR Antibody (Regeneron patent anti-APLNR, Research Use) | NBR-0385 |
| Immunomedics patent anti-Histone H2B | Histone H2B | Human Histone H2B Antibody (Immunomedics patent anti-Histone H2B, Research Use) | NBR-0386 |
| Immunomedics patent anti-Histone H3 | Histone H3 | Human Histone H3 Antibody (Immunomedics patent anti-Histone H3, Research Use) | NBR-0387 |
| Immunomedics patent anti-Histone H4 | Histone H4 | Human Histone H4 Antibody (Immunomedics patent anti-Histone H4, Research Use) | NBR-0388 |
| 19G9 | RG1 | Human RG1 Antibody (19G9, Research Use) | NBR-0389 |
| Regeneron patent anti-ANGPTL8 | ANGPTL8 | Human ANGPTL8 Antibody (Regeneron patent anti-ANGPTL8, Research Use) | NBR-0390 |
| Lilly patent anti-Pan-ELR+ | CXC-ELR | Human CXC-ELR Antibody (Lilly patent anti-Pan-ELR+, Research Use) | NBR-0391 |
| FHTR2163 | HtrA1 | Human HtrA1 Antibody (FHTR2163, Research Use) | NBR-0392 |
| Bayer patent anti-TIMP-1 | TIMP1 | Human TIMP1 Antibody (Bayer patent anti-TIMP-1, Research Use) | NBR-0393 |
| PF-06263507 | TPBG | Human TPBG Antibody (PF-06263507, Research Use) | NBR-0394 |
| OR2805 | CD163 | Human CD163 Antibody (OR2805, Research Use) | NBR-0395 |
| Canakinumab | IL-1B | Human IL-1B Antibody (Canakinumab, Research Use) | NBR-0396 |
| Lulizumab | CD28 | Human CD28 Antibody (Lulizumab, Research Use) | NBR-0397 |
| RG7841 | Ly6E | Human Ly6E Antibody (RG7841, Research Use) | NBR-0398 |
| CRX-014 | TIM-1 | Human TIM-1 Antibody (CRX-014, Research Use) | NBR-0399 |
| OBI-833 | Globo H | Human Globo H Antibody (OBI-833, Research Use) | NBR-0400 |
| ADCT-901 | KAAG1 | Human KAAG1 Antibody (ADCT-901, Research Use) | NBR-0401 |
| KHK2898 | CD98 | Human CD98 Antibody (KHK2898, Research Use) | NBR-0402 |
| ATN-658 | uPAR | Human uPAR Antibody (ATN-658, Research Use) | NBR-0403 |
| LIV-1205 | DLK-1 | Human DLK-1 Antibody (LIV-1205, Research Use) | NBR-0404 |
| Ontuxizumab | Endosialin | Human Endosialin Antibody (Ontuxizumab, Research Use) | NBR-0405 |
| Midwestern U. patent anti-ASPH | HAAH | Human HAAH Antibody (Midwestern U. patent anti-ASPH, Research Use) | NBR-0406 |
| Oxford Bio patent anti-Matriptase | Matriptase | Human Matriptase Antibody (Oxford Bio patent anti-Matriptase, Research Use) | NBR-0407 |
| Copenhagen Rigshospitalet patent anti-uPARAP | MRC2 | Human MRC2 Antibody (Copenhagen Rigshospitalet patent anti-uPARAP, Research Use) | NBR-0408 |
| AG02-ADC | PTGFRN | Human PTGFRN Antibody (AG02-ADC, Research Use) | NBR-0409 |
| Agensys patent anti-158P1D7 | 158P1D7 | Human 158P1D7 Antibody (Agensys patent anti-158P1D7, Research Use) | NBR-0410 |
| Centrose patent anti-dysadherin | dysadherin | Human dysadherin Antibody (Centrose patent anti-dysadherin, Research Use) | NBR-0411 |
| Bluefin patent anti-TMEFF1 | TMEFF1 | Human TMEFF1 Antibody (Bluefin patent anti-TMEFF1, Research Use) | NBR-0412 |
| Regeneron patent anti-RET | c-RET | Human c-RET Antibody (Regeneron patent anti-RET, Research Use) | NBR-0413 |
| Cantuzumab | C242 | Human C242 Antibody (Cantuzumab, Research Use) | NBR-0414 |
| Tamrintamab | DPEP3 | Human DPEP3 Antibody (Tamrintamab, Research Use) | NBR-0415 |
| Bivatuzumab | CD44v6 | Human CD44v6 Antibody (Bivatuzumab, Research Use) | NBR-0416 |
| abituzumab | Integrin AV | Human Integrin AV Antibody ( abituzumab, Research Use) | NBR-0417 |
| Minomic patent anti-Glypican 1 | Glypican 1 | Human Glypican 1 Antibody (Minomic patent anti-Glypican 1, Research Use) | NBR-0418 |
| Scripps patent anti-CD11a | Integrin A11 | Human Integrin A11 Antibody (Scripps patent anti-CD11a, Research Use) | NBR-0419 |
| GlycoNex patent anti-Lewis Y / B | Lewis Y / B antigen | Human Lewis Y / B antigen Antibody (GlycoNex patent anti-Lewis Y / B , Research Use) | NBR-0420 |
| Metuzumab | BSG2 | Human BSG2 Antibody (Metuzumab, Research Use) | NBR-0421 |
| F16-IL2 | Tenascin C | Human Tenascin C Antibody (F16-IL2, Research Use) | NBR-0422 |
| INSERM patent anti-Glycophorin A | Glycophorin A | Human Glycophorin A Antibody (INSERM patent anti-Glycophorin A, Research Use) | NBR-0423 |
| Ecromeximab | GD3 | Human GD3 Antibody (Ecromeximab, Research Use) | NBR-0424 |
| PF-03732010 | P-cadherin | Human P-cadherin Antibody ( PF-03732010, Research Use) | NBR-0425 |
| Rolinsatamab | PRLR | Human PRLR Antibody (Rolinsatamab, Research Use) | NBR-0426 |
| Cevostamab | IRTA2 | Human IRTA2 Antibody (Cevostamab, Research Use) | NBR-0427 |
| DEDN6526A | ETB-R | Human ETB-R Antibody (DEDN6526A, Research Use) | NBR-0428 |
| Samrotamab | LFL2 | Human LFL2 Antibody (Samrotamab, Research Use) | NBR-0429 |
| ASG-5ME | SLC44A4 | Human SLC44A4 Antibody (ASG-5ME, Research Use) | NBR-0430 |
| Sirtratumab | SLITRK6 | Human SLITRK6 Antibody (Sirtratumab, Research Use) | NBR-0431 |
| SAR428926 | LAMP1 | Human LAMP1 Antibody ( SAR428926, Research Use) | NBR-0432 |
| PF-06647263 | EFNA4 | Human EFNA4 Antibody (PF-06647263, Research Use) | NBR-0433 |
| Cusatuzumab | CD27L / CD70 | Human CD27L / CD70 Antibody (Cusatuzumab, Research Use) | NBR-0434 |
| CDX-0158 | c-Kit | Human c-Kit Antibody (CDX-0158, Research Use) | NBR-0435 |
| Tarextumab | Notch3 | Human Notch3 Antibody (Tarextumab, Research Use) | NBR-0436 |
| SGN-CD352A | SLAMF6 | Human SLAMF6 Antibody (SGN-CD352A, Research Use) | NBR-0437 |
| Lupartumab | C4.4a | Human C4.4a Antibody (Lupartumab, Research Use) | NBR-0438 |
| IMMU-114 | HLA-DR | Human HLA-DR Antibody (IMMU-114, Research Use) | NBR-0439 |
| Blinatumomab | CD3 | Human CD3 Antibody (Blinatumomab, Research Use) | NBR-0440 |
| Secukinumab | IL-17 | Human IL-17 Antibody (Secukinumab, Research Use) | NBR-0441 |
| Tralokinumab | IL-13 | Human IL-13 Antibody (Tralokinumab, Research Use) | NBR-0442 |
| Zanolimumab | CD4 | Human CD4 Antibody (Zanolimumab, Research Use) | NBR-0443 |
| Forerunner patent anti-DSG3 | DSG3 | Human DSG3 Antibody (Forerunner patent anti-DSG3, Research Use) | NBR-0444 |
| AFM13 | FCgR3A | Human FCgR3A Antibody ( AFM13, Research Use) | NBR-0445 |
| JNJ-69086420 | KLK2 | Human KLK2 Antibody (JNJ-69086420, Research Use) | NBR-0446 |
| K1-70 | TSHR | Human TSHR Antibody (K1-70, Research Use) | NBR-0447 |
| Mellitus patent anti-CD59 | CD59 | Human CD59 Antibody (Mellitus patent anti-CD59, Research Use) | NBR-0448 |
| Zymogenetics patent anti-BCMA / TACI | BCMA & TACI | Human BCMA & TACI Antibody (Zymogenetics patent anti-BCMA / TACI, Research Use) | NBR-0449 |
| Teplizumab | CD3e | Human CD3e Antibody (Teplizumab, Research Use) | NBR-0450 |
| Argenx patent anti-MuSK | MUSK | Human MUSK Antibody (Argenx patent anti-MuSK, Research Use) | NBR-0451 |
| CLN-619 | MICA | Human MICA Antibody (CLN-619, Research Use) | NBR-0452 |
| CDH17_A4 | CDH17 | Human CDH17 Antibody (CDH17_A4, Research Use) | NBR-0453 |
| Eculizumab | C5 | Human C5 Antibody (Eculizumab, Research Use) | NBR-0454 |
| PAR650097 | PAR-2 | Human PAR-2 Antibody (PAR650097, Research Use) | NBR-0455 |
| Nadecnemab | GFRA3 | Human GFRA3 Antibody (Nadecnemab, Research Use) | NBR-0456 |
| Atrosimab | TNFRSF1A | Human TNFRSF1A Antibody (Atrosimab, Research Use) | NBR-0457 |
| PY159 | TREM-1 | Human TREM-1 Antibody (PY159, Research Use) | NBR-0458 |
| RG6125 | Cadherin-11 | Human Cadherin-11 Antibody (RG6125, Research Use) | NBR-0459 |
| Wuhan U. patent anti-Nav1.9 | Nav1.9 | Human Nav1.9 Antibody (Wuhan U. patent anti-Nav1.9, Research Use) | NBR-0460 |
| U.Tokyo patent anti-TLR7 | TLR7 | Human TLR7 Antibody (U.Tokyo patent anti-TLR7, Research Use) | NBR-0461 |
| Leronlimab | CCR5 | Human CCR5 Antibody (Leronlimab, Research Use) | NBR-0462 |
| Drozitumab | DR5 / TRAILR2 | Human DR5 / TRAILR2 Antibody (Drozitumab, Research Use) | NBR-0463 |
| MEN1309 | LY75 | Human LY75 / CD205 Antibody (MEN1309, Research Use) | NBR-0464 |
| Adalimumab | TNFSF2 | Human TNFSF2 / TNFa Antibody (Adalimumab, Research Use) | NBR-0465 |
| HKT288 | CDH6 | Human CDH6 / K-Cadherin Antibody (HKT288, Research Use) | NBR-0466 |
| Genefrontier patent anti-CD69 | CD69 | Human CD69 Antibody (Genefrontier patent anti-CD69, Research Use) | NBR-0467 |
| Scripps Korea patent anti-CLEC14A | CLEC14A | Human CLEC14A Antibody (Scripps Korea patent anti-CLEC14A, Research Use) | NBR-0468 |
| Oxford Bio patent anti-CRTAM | CRTAM | Human CRTAM / CD355 Antibody (Oxford Bio patent anti-CRTAM, Research Use) | NBR-0469 |
| Med. Bio. Labs patent anti-CXADR | CXADR | Human CXADR Antibody (Med. Bio. Labs patent anti-CXADR, Research Use) | NBR-0470 |
| Novimmune patent anti-CXCL9 | CXCL9 | Human CXCL9 Antibody (Novimmune patent anti-CXCL9, Research Use) | NBR-0471 |
| INSERM patent anti-DC-SIGN | CD209 | Human DC-SIGN / CD209 Antibody (INSERM patent anti-DC-SIGN, Research Use) | NBR-0472 |
| Amgen patent anti-Ferroportin | SLC40A1 | Human SLC40A1 Antibody (Amgen patent anti-Ferroportin, Research Use) | NBR-0473 |
| CSL patent anti-G-CSFR | CSF3R | Human CSF3R / G-CSFR Antibody (CSL patent anti-G-CSFR, Research Use) | NBR-0474 |
| KHK patent anti-Haptoglobin | Haptoglobin | Human Haptoglobin Antibody (KHK patent anti-Haptoglobin, Research Use) | NBR-0475 |
| Wake Forest U. patent anti-IL-13RA2 | IL-13Ra2 | Human IL-13Ra2 / CD213a2 Antibody (Wake Forest U. patent anti-IL-13RA2, Research Use) | NBR-0476 |
| Cheng Kung U. patent anti-IL-20R1 | IL20RA | Human IL-20Ra Antibody (Cheng Kung U. patent anti-IL-20R1, Research Use) | NBR-0477 |
| Enokizumab | IL-9 | Human IL-9 Antibody (Enokizumab, Research Use) | NBR-0478 |
| Innate patent anti-KIR2DL | KIR2DL1 | Human KIR2DL1 / CD158a Antibody (Innate patent anti-KIR2DL, Research Use) | NBR-0479 |
| Novo Nordisk patent anti-PGLYRP1 | PGLYRP1 | Human PGLYRP1 / PGRP-S Antibody (Novo Nordisk patent anti-PGLYRP1, Research Use) | NBR-0480 |
| Diaccurate patent anti-sPLA2-GIB | PLA2G1B | Human PLA2G1B Antibody (Diaccurate patent anti-sPLA2-GIB, Research Use) | NBR-0481 |
| Oncomed patent anti-RSPO1 | RSPO1 | Human RSPO1 Antibody (Oncomed patent anti-RSPO1, Research Use) | NBR-0482 |
| Mapatumumab | TNFRSF10A | Human TNFRSF10A / TRAILR1 / CD261 Antibody (Mapatumumab, Research Use) | NBR-0483 |
| Regeneron patent anti-CD48 | CD48 | Human CD48 Antibody (Regeneron patent anti-CD48, Research Use) | NBR-0484 |
| Regeneron patent anti-PROKR1 | PROKR1 | Human GPR73 / PROKR1 Antibody (Regeneron patent anti-PROKR1, Research Use) | NBR-0485 |
| Genentech patent anti-Polyubiquitin | UBB | Human Polyubiquitin Antibody (Genentech patent anti-Polyubiquitin, Research Use) | NBR-0486 |
| SAR428926 | LAMP1 | Human LAMP1 / CD107a Antibody (SAR428926, Research Use) | NBR-0487 |
| Forerunner patent anti-DSG3 | DSG3 | Human DSG3 Antibody (Forerunner patent anti-DSG3, Research Use) | NBR-0488 |
| AFM13 | FcgR3a | Human FcgR3a / CD16a Antibody (AFM13, Research Use) | NBR-0489 |
| Mellitus patent anti-CD59 | CD59 | Human CD59 Antibody (Mellitus patent anti-CD59, Research Use) | NBR-0490 |
| Selicrelumab | CD40 | Human TNFRSF5 / CD40 Antibody (Selicrelumab, Research Use) | NBR-0491 |
| Domagrozumab | GDF8 | Human GDF8 / Myostatin Antibody (Domagrozumab, Research Use) | NBR-0492 |
| Abrilumab | ITGA4 & ITGB7 | Human Integrin a4b7 (ITGA4 & ITGB7) Antibody (Abrilumab, Research Use) | NBR-0493 |
| Amlitelimab | TNFSF4 | Human TNFSF4 / OX40L / CD252 Antibody (Amlitelimab, Research Use) | NBR-0494 |
| Abagovomab | MUC16 | Human MUC16 Antibody (Abagovomab, Research Use) | NBR-0495 |
| Birtamimab | SAA1 | Human Amyloid Alpha Antibody (Birtamimab, Research Use) | NBR-0496 |
| Aducanumab | APP | Human Amyloid Beta Antibody (Aducanumab, Research Use) | NBR-0497 |
| Abbott patent anti-Flt1 | VEGFR1 | Human VEGFR1 / FLT1 Antibody (Abbott patent anti-Flt1, Research Use) | NBR-0498 |
| Crenezumab | APP | Human Amyloid Beta Antibody (Crenezumab, Research Use) | NBR-0499 |
| DLX212 | APP | Human Amyloid Beta Antibody (DLX212, Research Use) | NBR-0500 |
| Acceleron patent anti-ActRIIB | ACVR2B | Human ACVR2B Antibody (Acceleron patent anti-ActRIIB, Research Use) | NBR-0501 |
| Gantenerumab | APP | Human Amyloid Beta Antibody (Gantenerumab, Research Use) | NBR-0502 |
| Actoxumab | N/A | Human Cdiff Toxin A Antibody (Actoxumab, Research Use) | NBR-0503 |
| GSK 933776 | APP | Human Amyloid Beta Antibody (GSK 933776, Research Use) | NBR-0504 |
| Ajinomoto patent anti-vWF | vWF | Human vWF Antibody (Ajinomoto patent anti-vWF, Research Use) | NBR-0505 |
| Alomfilimab | ICOS | Human ICOS / CD278 Antibody (Alomfilimab, Research Use) | NBR-0506 |
| Amgen patent anti-beta amyloid | APP | Human Amyloid Beta Antibody (Amgen patent anti-beta amyloid, Research Use) | NBR-0507 |
| MEDI3617 | ANGPT2 | Human ANGPT2 Antibody (MEDI3617, Research Use) | NBR-0508 |
| Apitegromab | GDF8 | Human GDF8 / Myostatin Antibody (Apitegromab, Research Use) | NBR-0509 |
| Zansecimab | ANGPT2 | Human ANGPT2 Antibody (Zansecimab, Research Use) | NBR-0510 |
| Nanyang Tech.U. patent anti-ANGPTL4 | ANGPTL4 | Human ANGPTL4 Antibody (Nanyang Tech.U. patent anti-ANGPTL4, Research Use) | NBR-0511 |
| Astegolimab | IL-1RL1 | Human IL-1RL1 / ST2 / IL-33R Antibody (Astegolimab, Research Use) | NBR-0512 |
| Avdoralimab | C5AR1 | Human Complement C5aR1 Antibody (Avdoralimab, Research Use) | NBR-0513 |
| Aveo anti-RON | MST1R | Human MSPR / RON / CD136 Antibody (Aveo anti-RON, Research Use) | NBR-0514 |
| MipasetamAb | AXL | Human AXL / UFO Antibody (MipasetamAb, Research Use) | NBR-0515 |
| Adebrelimab | CD274 | Human B7-H1 / PD-L1 / CD274 Antibody (Adebrelimab, Research Use) | NBR-0516 |
| Batoclimab | FCGRT | Human FcRn (FCGRT & B2M) Antibody (Batoclimab, Research Use) | NBR-0517 |
| Baylor patent anti-IFN alpha | IFNa1 | Human IFNa1 Antibody (Baylor patent anti-IFN alpha, Research Use) | NBR-0518 |
| Garivulimab | CD274 | Human B7-H1 / PD-L1 / CD274 Antibody (Garivulimab, Research Use) | NBR-0519 |
| Befovacimab | TFPI | Human TFPI Antibody (Befovacimab, Research Use) | NBR-0520 |
| Manelimab | CD274 | Human B7-H1 / PD-L1 / CD274 Antibody (Manelimab, Research Use) | NBR-0521 |
| Begelomab | DPP4 | Human DPP4 / CD26 Antibody (Begelomab, Research Use) | NBR-0522 |
| Pacmilimab | CD274 | Human B7-H1 / PD-L1 / CD274 Antibody (Pacmilimab, Research Use) | NBR-0523 |
| Sudubrilimab | CD274 | Human B7-H1 / PD-L1 / CD274 Antibody (Sudubrilimab, Research Use) | NBR-0524 |
| Sugemalimab | CD274 | Human B7-H1 / PD-L1 / CD274 Antibody (Sugemalimab, Research Use) | NBR-0525 |
| Prezalumab | ICOSLG | Human B7-H2 / ICOSL / CD275 Antibody (Prezalumab, Research Use) | NBR-0526 |
| Trellis patent anti-B7-H3 | CD276 | Human B7-H3 / CD276 Antibody (Trellis patent anti-B7-H3, Research Use) | NBR-0527 |
| Millennium patent anti-B7-H4 | VTCN1 | Human B7-H4 / VTCN1 Antibody (Millennium patent anti-B7-H4, Research Use) | NBR-0528 |
| Genentech anti-BACE1 | BACE1 | Human BACE1 Antibody (Genentech anti-BACE1, Research Use) | NBR-0529 |
| Blosozumab | SOST | Human SOST / Sclerostin Antibody (Blosozumab, Research Use) | NBR-0530 |
| Bococizumab | PCSK9 | Human PCSK9 Antibody (Bococizumab, Research Use) | NBR-0531 |
| Boehringer anti-PCSK9 | PCSK9 | Human PCSK9 Antibody (Boehringer anti-PCSK9, Research Use) | NBR-0532 |
| Eptinezumab | CALCA | Human CALCA / CGRP Antibody (Eptinezumab, Research Use) | NBR-0533 |
| Fremanezumab | CALCA | Human CALCA / CGRP Antibody (Fremanezumab, Research Use) | NBR-0534 |
| Galcanezumab | CALCA | Human CALCA / CGRP Antibody (Galcanezumab, Research Use) | NBR-0535 |
| Brigham and Women's patent anti-ABCB5 | ABCB5 | Human ABCB5 Antibody (Brigham and Women's patent anti-ABCB5, Research Use) | NBR-0536 |
| Nimacimab | CNR1 | Human CB1 / CNR1 Antibody (Nimacimab, Research Use) | NBR-0537 |
| Carlumab | CCL2 | Human CCL2 / MCP1 Antibody (Carlumab, Research Use) | NBR-0538 |
| NI-0701 | CCL5 | Human CCL5 / RANTES Antibody (NI-0701, Research Use) | NBR-0539 |
| Pierre Fabre patent anti-CD151 | CD151 | Human CD151 Antibody (Pierre Fabre patent anti-CD151, Research Use) | NBR-0540 |
| Centocor patent anti-CD147 | BSG | Human EMMPRIN / CD147 Antibody (Centocor patent anti-CD147, Research Use) | NBR-0541 |
| Denintuzumab | CD19 | Human CD19 Antibody (Denintuzumab, Research Use) | NBR-0542 |
| Duke U. patent anti-CD19 | CD19 | Human CD19 Antibody (Duke U. patent anti-CD19, Research Use) | NBR-0543 |
| Centocor patent anti-IL-25 | IL25 | Human IL-25 Antibody (Centocor patent anti-IL-25, Research Use) | NBR-0544 |
| CertolizumAb | TNFSF2 | Human TNFSF2 / TNFa Antibody (CertolizumAb, Research Use) | NBR-0545 |
| Siplizumab | CD2 | Human CD2 Antibody (Siplizumab, Research Use) | NBR-0546 |
| Chinese CDC patent anti-Interferon Alpha | IFNA1 | Human IFNa1 Antibody (Chinese CDC patent anti-Interferon Alpha, Research Use) | NBR-0547 |
| CNTO 2125 | APP | Human Amyloid Beta Antibody (CNTO 2125, Research Use) | NBR-0548 |
| CNTO 607 | IL13 | Human IL-13 Antibody (CNTO 607, Research Use) | NBR-0549 |
| CNTO5429 | TLR3 | Human TLR3 / CD283 Antibody (CNTO5429, Research Use) | NBR-0550 |
| Cobolimab | HAVCR2 | Human TIM-3 / HAVCR2 / CD366 Antibody (Cobolimab, Research Use) | NBR-0551 |
| Cofetuzumab | PTK7 | Human PTK7 / CCK4 Antibody (Cofetuzumab, Research Use) | NBR-0552 |
| Coltuximab | CD19 | Human CD19 Antibody (Coltuximab, Research Use) | NBR-0553 |
| Concizumab | TFPI | Human TFPI Antibody (Concizumab, Research Use) | NBR-0554 |
| Ripertamab | CD20 | Human CD20 Antibody (Ripertamab, Research Use) | NBR-0555 |
| TRU-015 | CD20 | Human CD20 Antibody (TRU-015, Research Use) | NBR-0556 |
| Ublituximab | CD20 | Human CD20 Antibody (Ublituximab, Research Use) | NBR-0557 |
| Veltuzumab | CD20 | Human CD20 Antibody (Veltuzumab, Research Use) | NBR-0558 |
| Zuberitamab | CD20 | Human CD20 Antibody (Zuberitamab, Research Use) | NBR-0559 |
| FR104 | CD28 | Human CD28 Antibody (FR104, Research Use) | NBR-0560 |
| Galiximab | CD80 | Human CD28L / CD80 Antibody (Galiximab, Research Use) | NBR-0561 |
| Coprelotamab | ERBB2 | Human ERBB2 / HER2 / CD340 Antibody (Coprelotamab, Research Use) | NBR-0562 |
| Cosibelimab | CD274 | Human B7-H1 / PD-L1 / CD274 Antibody (Cosibelimab, Research Use) | NBR-0563 |
| Crovalimab | C5 | Human Complement C5 Antibody (Crovalimab, Research Use) | NBR-0564 |
| CSIRO anti-amyloid Beta scFv | APP | Human Amyloid Beta Antibody (CSIRO anti-amyloid Beta scFv, Research Use) | NBR-0565 |
| Cudarolimab | TNFRSF4 | Human TNFRSF4 / OX40 / CD134 Antibody (Cudarolimab, Research Use) | NBR-0566 |
| Dalotuzumab | IGF1R | Human IGF1R / CD221 Antibody (Dalotuzumab, Research Use) | NBR-0567 |
| Dapirolizumab | CD40LG | Human TNFSF5 / CD40L / CD154 Antibody (Dapirolizumab, Research Use) | NBR-0568 |
| Visilizumab | CD3E | Human CD3 Antibody (Visilizumab, Research Use) | NBR-0569 |
| ITRI patent anti-CD34 | CD34 | Human CD34 Antibody (ITRI patent anti-CD34, Research Use) | NBR-0570 |
| Felzartamab | CD38 | Human CD38 Antibody (Felzartamab, Research Use) | NBR-0571 |
| Isatuximab | CD38 | Human CD38 Antibody (Isatuximab, Research Use) | NBR-0572 |
| Mezagitamab | CD38 | Human CD38 Antibody (Mezagitamab, Research Use) | NBR-0573 |
| Ibalizumab | CD4 | Human CD4 Antibody (Ibalizumab, Research Use) | NBR-0574 |
| Tregalizumab | CD4 | Human CD4 Antibody (Tregalizumab, Research Use) | NBR-0575 |
| TRX1 | CD4 | Human CD4 Antibody (TRX1, Research Use) | NBR-0576 |
| Depemokimab | IL-5 | Human IL-5 Antibody (Depemokimab, Research Use) | NBR-0577 |
| Derlotuximab | H1-0 | Human Histone H1 Antibody (Derlotuximab, Research Use) | NBR-0578 |
| Divozilimab | CD20 | Human CD20 Antibody (Divozilimab, Research Use) | NBR-0579 |
| Letaplimab | CD47 | Human CD47 Antibody (Letaplimab, Research Use) | NBR-0580 |
| Ligufalimab | CD47 | Human CD47 Antibody (Ligufalimab, Research Use) | NBR-0581 |
| LintuzumAb | CD33 | Human Siglec-3 / CD33 Antibody (LintuzumAb, Research Use) | NBR-0582 |
| Urabrelimab | CD47 | Human CD47 Antibody (Urabrelimab, Research Use) | NBR-0583 |
| Domantis patent anti-VEGF | VEGF | Human VEGF Antibody (Domantis patent anti-VEGF, Research Use) | NBR-0584 |
| Dompe patent anti-FOLR1 | FOLR1 | Human FOLR1 Antibody (Dompe patent anti-FOLR1, Research Use) | NBR-0585 |
| Gatralimab | CD52 | Human CD52 Antibody (Gatralimab, Research Use) | NBR-0586 |
| Quark patent anti-CD59 | CD59 | Human CD59 Antibody (Quark patent anti-CD59, Research Use) | NBR-0587 |
| Domvanalimab | TIGIT | Human TIGIT Antibody (Domvanalimab, Research Use) | NBR-0588 |
| Donanemab | Amyloid Beta | Human Amyloid Beta Antibody (Donanemab, Research Use) | NBR-0589 |
| GrisnilimAb | CD7 | Human CD7 Antibody (GrisnilimAb, Research Use) | NBR-0590 |
| Dostarlimab | CD279 | Human PDCD1 / PD-1 / CD279 Antibody (Dostarlimab, Research Use) | NBR-0591 |
| IladatuzumAb | CD79b | Human CD79b Antibody (IladatuzumAb, Research Use) | NBR-0592 |
| Genentech patent anti-CD83 | CD83 | Human CD83 Antibody (Genentech patent anti-CD83, Research Use) | NBR-0593 |
| Genentech patent anti-CD9 | CD9 | Human CD9 Antibody (Genentech patent anti-CD9, Research Use) | NBR-0594 |
| Stem Centrx patent anti-Cadherin-1 | CD324 | Human CDH1 / E-cadherin / CD324 Antibody (Stem Centrx patent anti-Cadherin-1, Research Use) | NBR-0595 |
| PF-03732010 | CDH3 | Human CDH3 / P-cadherin Antibody (PF-03732010, Research Use) | NBR-0596 |
| Chaim Sheba Med. Cntr. patent anti-CEACAM1 | CD66a | Human CEACAM1 / CD66a Antibody (Chaim Sheba Med. Cntr. patent anti-CEACAM1, Research Use) | NBR-0597 |
| CergutuzumAb | CD66e | Human CEACAM5 / CEA / CD66e Antibody (CergutuzumAb, Research Use) | NBR-0598 |
| Ebdarokimab | IL-12b | Human IL-12b Antibody (Ebdarokimab, Research Use) | NBR-0599 |
| Tusamitamab | CD66e | Human CEACAM5 / CEA / CD66e Antibody (Tusamitamab, Research Use) | NBR-0600 |
| Ebronucimab | PCSK9 | Human PCSK9 Antibody (Ebronucimab, Research Use) | NBR-0601 |
| Tinurilimab | CD66c | Human CEACAM6 / CD66c Antibody (Tinurilimab, Research Use) | NBR-0602 |
| Academia Sinica patent anti-Clathrin Heavy Chain | CHC | Human Clathrin Heavy Chain / CHC Antibody (Academia Sinica patent anti-Clathrin Heavy Chain, Research Use) | NBR-0603 |
| Elsilimomab | IL-6 | Human IL-6 / IFNb2 Antibody (Elsilimomab, Research Use) | NBR-0604 |
| Emory U. anti-CD40 | CD40 | Human TNFRSF5 / CD40 Antibody (Emory U. anti-CD40, Research Use) | NBR-0605 |
| BIIB059 | CLEC4C | Human CLEC4C Antibody (BIIB059, Research Use) | NBR-0606 |
| Lendalizumab | Complement C5 | Human Complement C5 Antibody (Lendalizumab, Research Use) | NBR-0607 |
| Ravulizumab | Complement C5 | Human Complement C5 Antibody (Ravulizumab, Research Use) | NBR-0608 |
| Enoticumab | DLL4 | Human DLL4 Antibody (Enoticumab, Research Use) | NBR-0609 |
| G2 patent anti-C5aR | Complement C5aR1 | Human Complement C5aR1 Antibody (G2 patent anti-C5aR, Research Use) | NBR-0610 |
| Lampalizumab | Complement Factor D | Human Complement Factor D Antibody (Lampalizumab, Research Use) | NBR-0611 |
| Epitomics patent anti-TNFα | TNFSF2 | Human TNFSF2 / TNFa Antibody (Epitomics patent anti-TNFα, Research Use) | NBR-0612 |
| Emactuzumab | CSF1R | Human CSF1R / M-CSFR / CD115 Antibody (Emactuzumab, Research Use) | NBR-0613 |
| LY3022855 | CSF1R | Human CSF1R / M-CSFR / CD115 Antibody (LY3022855, Research Use) | NBR-0614 |
| Gimsilumab | CSF2 | Human CSF2 / GM-CSF Antibody (Gimsilumab, Research Use) | NBR-0615 |
| Lenzilumab | CSF2 | Human CSF2 / GM-CSF Antibody (Lenzilumab, Research Use) | NBR-0616 |
| Namilumab | CSF2 | Human CSF2 / GM-CSF Antibody (Namilumab, Research Use) | NBR-0617 |
| Etrolizumab | ITGA4 & ITGB7 | Human Integrin a4b7 (ITGA4 & ITGB7) Antibody (Etrolizumab, Research Use) | NBR-0618 |
| Evolocumab | PCSK9 | Human PCSK9 Antibody (Evolocumab, Research Use) | NBR-0619 |
| Expression DD patent anti-SIP | Sphingosine-1-phosphate | Human Sphingosine-1-phosphate Antibody (Expression DD patent anti-SIP, Research Use) | NBR-0620 |
| Finotonlimab | CD279 | Human PDCD1 / PD-1 / CD279 Antibody (Finotonlimab, Research Use) | NBR-0621 |
| Flanvotumab | TRP1 | Human TRP1 / TYRP1 Antibody (Flanvotumab, Research Use) | NBR-0622 |
| Nurulimab | CD152 | Human CTLA-4 / CD152 Antibody (Nurulimab, Research Use) | NBR-0623 |
| Tremelimumab | CD152 | Human CTLA-4 / CD152 Antibody (Tremelimumab, Research Use) | NBR-0624 |
| Zalifrelimab | CD152 | Human CTLA-4 / CD152 Antibody (Zalifrelimab, Research Use) | NBR-0625 |
| CAT-2200 | CTLA-8 | Human CTLA-8 / IL-17a Antibody (CAT-2200, Research Use) | NBR-0626 |
| Ixekizumab | CTLA-8 | Human CTLA-8 / IL-17a Antibody (Ixekizumab, Research Use) | NBR-0627 |
| Netakimab | CTLA-8 | Human CTLA-8 / IL-17a Antibody (Netakimab, Research Use) | NBR-0628 |
| Perakizumab | CTLA-8 | Human CTLA-8 / IL-17a Antibody (Perakizumab, Research Use) | NBR-0629 |
| UCB patent anti-IL-17 | CTLA-8 | Human CTLA-8 / IL-17a Antibody (UCB patent anti-IL-17, Research Use) | NBR-0630 |
| Vunakizumab | CTLA-8 | Human CTLA-8 / IL-17a Antibody (Vunakizumab, Research Use) | NBR-0631 |
| Fontolizumab | IFNg | Human IFNg Antibody (Fontolizumab, Research Use) | NBR-0632 |
| NI-0801 | CXCL10 | Human CXCL10 / IP-10 Antibody (NI-0801, Research Use) | NBR-0633 |
| Genentech anti-CXCL12 | CXCL12 | Human CXCL12 / SDF1a Antibody (Genentech anti-CXCL12, Research Use) | NBR-0634 |
| ABX-IL8 | CXCL8 | Human CXCL8 / IL-8 Antibody (ABX-IL8, Research Use) | NBR-0635 |
| Genentech patent anti-IL-8 | CXCL8 | Human CXCL8 / IL-8 Antibody (Genentech patent anti-IL-8, Research Use) | NBR-0636 |
| Foralumab | CD3e | Human CD3e Antibody (Foralumab, Research Use) | NBR-0637 |
| Dana-Farber patent anti-CXCR4 | CXCR4 | Human CXCR4 / CD184 Antibody (Dana-Farber patent anti-CXCR4, Research Use) | NBR-0638 |
| Forerunner patent anti-ICAM-3 | ICAM3 | Human ICAM3 / CD50 Antibody (Forerunner patent anti-ICAM-3, Research Use) | NBR-0639 |
| Forerunner patent anti-Muc 17 | MUC17 | Human MUC17 Antibody (Forerunner patent anti-Muc 17, Research Use) | NBR-0640 |
| Fox Chase patent anti-TEM7R | PLXDC2 | Human TEM7R / PLXDC2 Antibody (Fox Chase patent anti-TEM7R, Research Use) | NBR-0641 |
| Fresolimumab | TGFB1 | Human TGFb1 Antibody (Fresolimumab, Research Use) | NBR-0642 |
| Frovocimab | PCSK9 | Human PCSK9 Antibody (Frovocimab, Research Use) | NBR-0643 |
| Smart Targeting patent anti-DLL4 | DLL4 | Human DLL4 Antibody (Smart Targeting patent anti-DLL4, Research Use) | NBR-0644 |
| Gancotamab | ERBB2 | Human ERBB2 / HER2 / CD340 Antibody (Gancotamab, Research Use) | NBR-0645 |
| Gatipotuzumab | MUC1 | Human MUC1 Antibody (Gatipotuzumab, Research Use) | NBR-0646 |
| Parsatuzumab | EGFL7 | Human EGFL7 Antibody (Parsatuzumab, Research Use) | NBR-0647 |
| Genentech patent anti-Factor B | CFB | Human Complement Factor B Antibody (Genentech patent anti-Factor B, Research Use) | NBR-0648 |
| Genentech patent anti-Notch3 | NOTCH3 | Human NOTCH3 Antibody (Genentech patent anti-Notch3, Research Use) | NBR-0649 |
| Adecatumumab | EPCAM | Human EpCAM / TROP1 / CD326 Antibody (Adecatumumab, Research Use) | NBR-0650 |
| Georgetown U. patent anti-Amyloid Beta | APP | Human Amyloid Beta Antibody (Georgetown U. patent anti-Amyloid Beta, Research Use) | NBR-0651 |
| Geptanolimab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Geptanolimab, Research Use) | NBR-0652 |
| Gevokizumab | IL-1b | Human IL-1b Antibody (Gevokizumab, Research Use) | NBR-0653 |
| Giloralimab | CD40 | Human TNFRSF5 / CD40 Antibody (Giloralimab, Research Use) | NBR-0654 |
| 7A7 | ERBB1 | Human ERBB1 / EGFR / HER1 Antibody (7A7, Research Use) | NBR-0655 |
| Chinese Mil.Med.Sci. patent anti-EGFR | ERBB1 | Human ERBB1 / EGFR / HER1 Antibody (Chinese Mil.Med.Sci. patent anti-EGFR, Research Use) | NBR-0656 |
| Demupitamab | ERBB1 | Human ERBB1 / EGFR / HER1 Antibody (Demupitamab, Research Use) | NBR-0657 |
| Depatuxizumab | ERBB1 | Human ERBB1 / EGFR / HER1 Antibody (Depatuxizumab, Research Use) | NBR-0658 |
| Duke D2C7 | ERBB1 | Human ERBB1 / EGFR / HER1 Antibody (Duke D2C7, Research Use) | NBR-0659 |
| Imgatuzumab | ERBB1 | Human ERBB1 / EGFR / HER1 Antibody (Imgatuzumab, Research Use) | NBR-0660 |
| LaprituximAb | ERBB1 | Human ERBB1 / EGFR / HER1 Antibody (LaprituximAb, Research Use) | NBR-0661 |
| Matuzumab | ERBB1 | Human ERBB1 / EGFR / HER1 Antibody (Matuzumab, Research Use) | NBR-0662 |
| Necitumumab | ERBB1 | Human ERBB1 / EGFR / HER1 Antibody (Necitumumab, Research Use) | NBR-0663 |
| Golimumab | TNFSF2 | Human TNFSF2 / TNFa Antibody (Golimumab, Research Use) | NBR-0664 |
| Pimurutamab | ERBB1 | Human ERBB1 / EGFR / HER1 Antibody (Pimurutamab, Research Use) | NBR-0665 |
| Shanghai Cancer Inst patent anti-EGFRvIII | ERBB1 | Human ERBB1 / EGFR / HER1 Antibody (Shanghai Cancer Inst patent anti-EGFRvIII, Research Use) | NBR-0666 |
| Zalutumumab | ERBB1 | Human ERBB1 / EGFR / HER1 Antibody (Zalutumumab, Research Use) | NBR-0667 |
| Ibritumomab | CD20 | Human CD20 Antibody (Ibritumomab, Research Use) | NBR-0668 |
| Icatolimab | BTLA | Human BTLA / CD272 Antibody (Icatolimab, Research Use) | NBR-0669 |
| Ifabotuzumab | EphA3 | Human EphA3 Antibody (Ifabotuzumab, Research Use) | NBR-0670 |
| Hersintuzumab | ERBB2 | Human ERBB2 / HER2 / CD340 Antibody (Hersintuzumab, Research Use) | NBR-0671 |
| Margetuximab | ERBB2 | Human ERBB2 / HER2 / CD340 Antibody (Margetuximab, Research Use) | NBR-0672 |
| Timigutuzumab | ERBB2 | Human ERBB2 / HER2 / CD340 Antibody (Timigutuzumab, Research Use) | NBR-0673 |
| Barecetamab | ERBB3 | Human ERBB3 / HER3 Antibody (Barecetamab, Research Use) | NBR-0674 |
| Lumretuzumab | ERBB3 | Human ERBB3 / HER3 Antibody (Lumretuzumab, Research Use) | NBR-0675 |
| Imclone 6.64 | KDR | Human VEGFR2 / KDR / CD309 Antibody (Imclone 6.64, Research Use) | NBR-0676 |
| Immunomedics hA19 | CD19 | Human CD19 Antibody (Immunomedics hA19, Research Use) | NBR-0677 |
| Abelacimab | F11 | Human F11 / Factor XI Antibody (Abelacimab, Research Use) | NBR-0678 |
| Lumiliximab | FCER2 | Human FceR2 / CD23 Antibody (Lumiliximab, Research Use) | NBR-0679 |
| DFRF4539A | FcRL5 | Human FcRL5 / IRTA2 Antibody (DFRF4539A, Research Use) | NBR-0680 |
| Immunomedics patent anti-IGF-1R | IGF1R | Human IGF1R / CD221 Antibody (Immunomedics patent anti-IGF-1R, Research Use) | NBR-0681 |
| Imperial College anti-DDR1 | DDR1 | Human DDR1 / CD167a Antibody (Imperial College anti-DDR1, Research Use) | NBR-0682 |
| Lilly patent anti-FGFR-1 | FGFR1 | Human FGFR1 / CD331 Antibody (Lilly patent anti-FGFR-1, Research Use) | NBR-0683 |
| INSERM patent anti-CO-029 | TSPAN8 | Human TSPAN8 Antibody (INSERM patent anti-CO-029, Research Use) | NBR-0684 |
| Radretumab | FN1 | Human Fibronectin Antibody (Radretumab, Research Use) | NBR-0685 |
| PelgifatamAb | FOLH1 | Human FOLH1 / PSMA Antibody (PelgifatamAb, Research Use) | NBR-0686 |
| Iparomlimab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Iparomlimab, Research Use) | NBR-0687 |
| Vantictumab | FZD | Human FZD Antibody (Vantictumab, Research Use) | NBR-0688 |
| Ivuxolimab | TNFRSF4 | Human TNFRSF4 / OX40 / CD134 Antibody (Ivuxolimab, Research Use) | NBR-0689 |
| Jackson Foundation patent anti-ERG | ERG | Human ERG Antibody (Jackson Foundation patent anti-ERG, Research Use) | NBR-0690 |
| Dinutuximab | N/A | Human GD2 Antibody (Dinutuximab, Research Use) | NBR-0691 |
| EMD 273063 | N/A | Human GD2 Antibody (EMD 273063, Research Use) | NBR-0692 |
| Korea Natl.Cancer Ctr. patent anti-GITR | TNFRSF18 | Human TNFRSF18 / GITR / CD357 Antibody (Korea Natl.Cancer Ctr. patent anti-GITR, Research Use) | NBR-0693 |
| Korea RIBB patent anti-cMet | MET | Human HGFR / c-Met Antibody (Korea RIBB patent anti-cMet, Research Use) | NBR-0694 |
| Kumamoto U. patent anti-Amyloid Beta | APP | Human Amyloid Beta Antibody (Kumamoto U. patent anti-Amyloid Beta, Research Use) | NBR-0695 |
| Latozinemab | SORT1 | Human Sortilin / SORT1 Antibody (Latozinemab, Research Use) | NBR-0696 |
| Lemzoparlimab | CD47 | Human CD47 Antibody (Lemzoparlimab, Research Use) | NBR-0697 |
| Lilotomab | CD37 | Human TSPAN26 / CD37 Antibody (Lilotomab, Research Use) | NBR-0698 |
| Lodapolimab | CD274 | Human B7-H1 / PD-L1 / CD274 Antibody (Lodapolimab, Research Use) | NBR-0699 |
| Lodelcizumab | PCSK9 | Human PCSK9 Antibody (Lodelcizumab, Research Use) | NBR-0700 |
| Facet patent anti-GPR64 | ADGRG2 | Human GPR64 / ADGRG2 Antibody (Facet patent anti-GPR64, Research Use) | NBR-0701 |
| LonigutamAb | IGF1R | Human IGF1R / CD221 Antibody (LonigutamAb, Research Use) | NBR-0702 |
| LosatuxizumAb | ERBB1 | Human ERBB1 / EGFR / HER1 Antibody (LosatuxizumAb, Research Use) | NBR-0703 |
| Ludwig-Maximilians U. anti_Hepsin | HAMP | Human Hepcidin / HAMP Antibody (Ludwig-Maximilians U. anti_Hepsin, Research Use) | NBR-0704 |
| LY2787106 | HAMP | Human Hepcidin / HAMP Antibody (LY2787106, Research Use) | NBR-0705 |
| Macrogenics patent anti-KID3 | KID3 | Human KID3 Antibody (Macrogenics patent anti-KID3, Research Use) | NBR-0706 |
| TAK-701 | HGF | Human HGF / SF Antibody (TAK-701, Research Use) | NBR-0707 |
| Metheresis patent anti-Met | MET | Human HGFR / c-Met Antibody (Metheresis patent anti-Met, Research Use) | NBR-0708 |
| SAIT301 | MET | Human HGFR / c-Met Antibody (SAIT301, Research Use) | NBR-0709 |
| Merck anti-Amyloid beta 19.3 | APP | Human Amyloid Beta Antibody (Merck anti-Amyloid beta 19.3, Research Use) | NBR-0710 |
| Merck patent anti-Amyloid Beta | APP | Human Amyloid Beta Antibody (Merck patent anti-Amyloid Beta, Research Use) | NBR-0711 |
| MirzotamAb | CD276 | Human B7-H3 / CD276 Antibody (MirzotamAb, Research Use) | NBR-0712 |
| Modotuximab | ERBB1 | Human ERBB1 / EGFR / HER1 Antibody (Modotuximab, Research Use) | NBR-0713 |
| Bersanlimab | ICAM1 | Human ICAM1 / CD54 Antibody (Bersanlimab, Research Use) | NBR-0714 |
| MEDI-570 | ICOS | Human ICOS / CD278 Antibody (MEDI-570, Research Use) | NBR-0715 |
| AMG 811 | IFNg | Human IFNg Antibody (AMG 811, Research Use) | NBR-0716 |
| Emapalumab | IFNg | Human IFNg Antibody (Emapalumab, Research Use) | NBR-0717 |
| Quilizumab | IGHE | Human IgE (M1 prime) Antibody (Quilizumab, Research Use) | NBR-0718 |
| Ligelizumab | IGHE | Human IgE Antibody (Ligelizumab, Research Use) | NBR-0719 |
| Mupadolimab | NT5E | Human NT5E / CD73 Antibody (Mupadolimab, Research Use) | NBR-0720 |
| Talizumab | IGHE | Human IgE Antibody (Talizumab, Research Use) | NBR-0721 |
| NaptumomAb | TPBG | Human TPBG Antibody (NaptumomAb, Research Use) | NBR-0722 |
| Figitumumab | IGF1R | Human IGF1R / CD221 Antibody (Figitumumab, Research Use) | NBR-0723 |
| Ganitumab | IGF1R | Human IGF1R / CD221 Antibody (Ganitumab, Research Use) | NBR-0724 |
| NIH patent anti-Mesothelin | MSLN | Human Mesothelin Antibody (NIH patent anti-Mesothelin, Research Use) | NBR-0725 |
| Nimotuzumab | ERBB1 | Human ERBB1 / EGFR / HER1 Antibody (Nimotuzumab, Research Use) | NBR-0726 |
| DX-2647 | IGF2 | Human IGF2 Antibody (DX-2647, Research Use) | NBR-0727 |
| BT-063 | IL-10 | Human IL-10 Antibody (BT-063, Research Use) | NBR-0728 |
| Briakinumab | IL-12a | Human IL-12 (IL-12a & IL-12b) Antibody (Briakinumab, Research Use) | NBR-0729 |
| Nipocalimab | FcRn | Human FcRn (FCGRT & B2M) Antibody (Nipocalimab, Research Use) | NBR-0730 |
| Abrezekimab | IL-13 | Human IL-13 Antibody (Abrezekimab, Research Use) | NBR-0731 |
| Cendakimab | IL-13 | Human IL-13 Antibody (Cendakimab, Research Use) | NBR-0732 |
| Dectrekumab | IL-13 | Human IL-13 Antibody (Dectrekumab, Research Use) | NBR-0733 |
| GSK 679586 | IL-13 | Human IL-13 Antibody (GSK 679586, Research Use) | NBR-0734 |
| H2L6 | IL-13 | Human IL-13 Antibody (H2L6, Research Use) | NBR-0735 |
| IMA-026 | IL-13 | Human IL-13 Antibody (IMA-026, Research Use) | NBR-0736 |
| Lebrikizumab | IL-13 | Human IL-13 Antibody (Lebrikizumab, Research Use) | NBR-0737 |
| M1295 | IL-13 | Human IL-13 Antibody (M1295, Research Use) | NBR-0738 |
| Nofazinlimab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Nofazinlimab, Research Use) | NBR-0739 |
| Novartis patent anti-CD45 | PTPRC | Human PTPRC / CD45 Antibody (Novartis patent anti-CD45, Research Use) | NBR-0740 |
| DISC0280 | IL-15 | Human IL-15 Antibody (DISC0280, Research Use) | NBR-0741 |
| ABT-325 | IL-18 | Human IL-18 Antibody (ABT-325, Research Use) | NBR-0742 |
| Bermekimab | IL-1a | Human IL-1a Antibody (Bermekimab, Research Use) | NBR-0743 |
| CDP484 | IL-1b | Human IL-1b Antibody (CDP484, Research Use) | NBR-0744 |
| Novo Nordisk patent anti-Factor VIII | F8 | Human F8 / Factor VIII Antibody (Novo Nordisk patent anti-Factor VIII, Research Use) | NBR-0745 |
| Melrilimab | IL-1RL1 | Human IL-1RL1 / ST2 / IL-33R Antibody (Melrilimab, Research Use) | NBR-0746 |
| Cheng Kung U. patent anti-IL-20 | IL-20 | Human IL-20 Antibody (Cheng Kung U. patent anti-IL-20, Research Use) | NBR-0747 |
| Avizakimab | IL-21 | Human IL-21 Antibody (Avizakimab, Research Use) | NBR-0748 |
| Brazikumab | IL-23 | Human IL-23 Antibody (Brazikumab, Research Use) | NBR-0749 |
| LY2525623 | IL-23 | Human IL-23 Antibody (LY2525623, Research Use) | NBR-0750 |
| Mirikizumab | IL-23 | Human IL-23 Antibody (Mirikizumab, Research Use) | NBR-0751 |
| Risankizumab | IL-23 | Human IL-23a Antibody (Risankizumab, Research Use) | NBR-0752 |
| CamidanlumAb | IL-2Ra | Human IL-2Ra / CD25 Antibody (CamidanlumAb, Research Use) | NBR-0753 |
| Ocaratuzumab | CD20 | Human CD20 Antibody (Ocaratuzumab, Research Use) | NBR-0754 |
| Ociperlimab | TIGIT | Human TIGIT Antibody (Ociperlimab, Research Use) | NBR-0755 |
| Ocrelizumab | CD20 | Human CD20 Antibody (Ocrelizumab, Research Use) | NBR-0756 |
| Itepekimab | IL-33 | Human IL-33 Antibody (Itepekimab, Research Use) | NBR-0757 |
| Ofatumumab | CD20 | Human CD20 Antibody (Ofatumumab, Research Use) | NBR-0758 |
| MEDI2045 | IL-4Ra | Human IL-4Ra / CD124 Antibody (MEDI2045, Research Use) | NBR-0759 |
| Abgenix anti-IL-5 | IL-5 | Human IL-5 Antibody (Abgenix anti-IL-5, Research Use) | NBR-0760 |
| Okayama U. patent anti-oxLDL | OLR1 | Human oxLDL Antibody (Okayama U. patent anti-oxLDL, Research Use) | NBR-0761 |
| Chugai SK2 | IL-6 | Human IL-6 / IFNb2 Antibody (Chugai SK2, Research Use) | NBR-0762 |
| CSTRI patent anti-IL-6 | IL-6 | Human IL-6 / IFNb2 Antibody (CSTRI patent anti-IL-6, Research Use) | NBR-0763 |
| Medarex patent anti-IL-6 | IL-6 | Human IL-6 / IFNb2 Antibody (Medarex patent anti-IL-6, Research Use) | NBR-0764 |
| MEDI 5117 | IL-6 | Human IL-6 / IFNb2 Antibody (MEDI 5117, Research Use) | NBR-0765 |
| Merck patent anti-IL-6 | IL-6 | Human IL-6 / IFNb2 Antibody (Merck patent anti-IL-6, Research Use) | NBR-0766 |
| Olinvacimab | KDR | Human VEGFR2 / KDR / CD309 Antibody (Olinvacimab, Research Use) | NBR-0767 |
| Siltuximab | IL-6 | Human IL-6 / IFNb2 Antibody (Siltuximab, Research Use) | NBR-0768 |
| Sirukumab | IL-6 | Human IL-6 / IFNb2 Antibody (Sirukumab, Research Use) | NBR-0769 |
| Ziltivekimab | IL-6 | Human IL-6 / IFNb2 Antibody (Ziltivekimab, Research Use) | NBR-0770 |
| APX007 | IL-6Ra | Human IL-6Ra / CD126 Antibody (APX007, Research Use) | NBR-0771 |
| Levilimab | IL-6Ra | Human IL-6Ra / CD126 Antibody (Levilimab, Research Use) | NBR-0772 |
| Sapelizumab | IL-6Ra | Human IL-6Ra / CD126 Antibody (Sapelizumab, Research Use) | NBR-0773 |
| Olokizumab | IL-6 | Human IL-6 / IFNb2 Antibody (Olokizumab, Research Use) | NBR-0774 |
| Omalizumab | IGHE | Human IgE Antibody (Omalizumab, Research Use) | NBR-0775 |
| Omburtamab | CD276 | Human B7-H3 / CD276 Antibody (Omburtamab, Research Use) | NBR-0776 |
| PF-06342674 | IL-7Ra | Human IL-7Ra / CD127 Antibody (PF-06342674, Research Use) | NBR-0777 |
| Ongericimab | PCSK9 | Human PCSK9 Antibody (Ongericimab, Research Use) | NBR-0778 |
| Vatelizumab | ITGA2 & ITGB1 | Human Integrin a2b1 (ITGA2 & ITGB1) Antibody (Vatelizumab, Research Use) | NBR-0779 |
| BMS patent anti-Integrin α5β1 | ITGA5 & ITGB1 | Human Integrin a5b1 (ITGA5 & ITGB1) Antibody (BMS patent anti-Integrin α5β1, Research Use) | NBR-0780 |
| Efalizumab | ITGAL | Human Integrin aL / ITGAL / CD11a Antibody (Efalizumab, Research Use) | NBR-0781 |
| Abituzumab | ITGAV | Human Integrin aV / ITGAV / CD51 Antibody (Abituzumab, Research Use) | NBR-0782 |
| Intetumumab | ITGAV | Human Integrin aV / ITGAV / CD51 Antibody (Intetumumab, Research Use) | NBR-0783 |
| Etaracizumab | ITGAV & ITGB3 | Human Integrin aVb3 (ITGAV & ITGB3) Antibody (Etaracizumab, Research Use) | NBR-0784 |
| Opicinumab | LINGO1 | Human LINGO1 Antibody (Opicinumab, Research Use) | NBR-0785 |
| Oportuzumab | EPCAM | Human EpCAM / TROP1 / CD326 Antibody (Oportuzumab, Research Use) | NBR-0786 |
| Encelimab | LAG3 | Human LAG3 / CD223 Antibody (Encelimab, Research Use) | NBR-0787 |
| Favezelimab | LAG3 | Human LAG3 / CD223 Antibody (Favezelimab, Research Use) | NBR-0788 |
| Fianlimab | LAG3 | Human LAG3 / CD223 Antibody (Fianlimab, Research Use) | NBR-0789 |
| Ieramilimab | LAG3 | Human LAG3 / CD223 Antibody (Ieramilimab, Research Use) | NBR-0790 |
| Miptenalimab | LAG3 | Human LAG3 / CD223 Antibody (Miptenalimab, Research Use) | NBR-0791 |
| Opucolimab | CD274 | Human B7-H1 / PD-L1 / CD274 Antibody (Opucolimab, Research Use) | NBR-0792 |
| LadiratuzumAb | SLC39A6 | Human LIV-1 / SLC39A6 Antibody (LadiratuzumAb, Research Use) | NBR-0793 |
| Organon patent anti-CD27 | CD27 | Human TNFRSF7 / CD27 Antibody (Organon patent anti-CD27, Research Use) | NBR-0794 |
| Orilanolimab | FCGRT | Human FcRn (FCGRT & B2M) Antibody (Orilanolimab, Research Use) | NBR-0795 |
| Orticumab | OLR1 | Human oxLDL Antibody (Orticumab, Research Use) | NBR-0796 |
| ORY012 | AXL | Human AXL / UFO Antibody (ORY012, Research Use) | NBR-0797 |
| BMS-986148 | MSLN | Human Mesothelin Antibody (BMS-986148, Research Use) | NBR-0798 |
| Osocimab | F11 | Human F11 / Factor XI Antibody (Osocimab, Research Use) | NBR-0799 |
| Yeda patent anti-MMP-9 | MMP9 | Human MMP9 Antibody (Yeda patent anti-MMP-9, Research Use) | NBR-0800 |
| Otelixizumab | CD3E | Human CD3 Antibody (Otelixizumab, Research Use) | NBR-0801 |
| Otilimab | CSF2 | Human CSF2 / GM-CSF Antibody (Otilimab, Research Use) | NBR-0802 |
| AR20.5 | MUC1 | Human MUC1 Antibody (AR20.5, Research Use) | NBR-0803 |
| Otlertuzumab | CD37 | Human TSPAN26 / CD37 Antibody (Otlertuzumab, Research Use) | NBR-0804 |
| Oxford Brookes U. patent anti-Activin Beta-B | INHBB | Human INHBB / Activin B Antibody (Oxford Brookes U. patent anti-Activin Beta-B, Research Use) | NBR-0805 |
| Imaprelimab | MCAM | Human MUC18 / MCAM / CD146 Antibody (Imaprelimab, Research Use) | NBR-0806 |
| AS2886401-00 | NGF | Human NGF / bNGF Antibody (AS2886401-00, Research Use) | NBR-0807 |
| Fasinumab | NGF | Human NGF / bNGF Antibody (Fasinumab, Research Use) | NBR-0808 |
| MEDI-578 | NGF | Human NGF / bNGF Antibody (MEDI-578, Research Use) | NBR-0809 |
| PG110 | NGF | Human NGF / bNGF Antibody (PG110, Research Use) | NBR-0810 |
| Uliledlimab | NT5E | Human NT5E / CD73 Antibody (Uliledlimab, Research Use) | NBR-0811 |
| Pfizer patent anti-Notch1 | NOTCH1 | Human NOTCH1 Antibody (Pfizer patent anti-Notch1, Research Use) | NBR-0812 |
| Vixarelimab | OSMR | Human OSMR Antibody (Vixarelimab, Research Use) | NBR-0813 |
| ASK8007 | SPP1 | Human Osteopontin Antibody (ASK8007, Research Use) | NBR-0814 |
| Plonmarlimab | CSF2 | Human CSF2 / GM-CSF Antibody (Plonmarlimab, Research Use) | NBR-0815 |
| Ponezumab | APP | Human Amyloid Beta Antibody (Ponezumab, Research Use) | NBR-0816 |
| Zelminemab | PAC1 | Human PAC1 Antibody (Zelminemab, Research Use) | NBR-0817 |
| Ponsegromab | GDF15 | Human GDF15 / MIC-1 Antibody (Ponsegromab, Research Use) | NBR-0818 |
| Amgen patent anti-PAR-2 | PAR2 | Human PAR2 Antibody (Amgen patent anti-PAR-2, Research Use) | NBR-0819 |
| Pozelimab | C5 | Human Complement C5 Antibody (Pozelimab, Research Use) | NBR-0820 |
| U.Penn. patent anti-PCLA | PLCA | Human PCLA Antibody (U.Penn. patent anti-PCLA, Research Use) | NBR-0821 |
| Prolgolimab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Prolgolimab, Research Use) | NBR-0822 |
| Quark patent anti-ENDO 180 | MRC2 | Human MRC2 / CD280 Antibody (Quark patent anti-ENDO 180, Research Use) | NBR-0823 |
| Quavonlimab | CTLA4 | Human CTLA-4 / CD152 Antibody (Quavonlimab, Research Use) | NBR-0824 |
| Racotumomab | ST3GAL5 | Human GM3 Antibody (Racotumomab, Research Use) | NBR-0825 |
| Merck patent anti-PCSK9 | PCSK9 | Human PCSK9 Antibody (Merck patent anti-PCSK9, Research Use) | NBR-0826 |
| Ralpancizumab | PCSK9 | Human PCSK9 Antibody (Ralpancizumab, Research Use) | NBR-0827 |
| Recaticimab | PCSK9 | Human PCSK9 Antibody (Recaticimab, Research Use) | NBR-0828 |
| RG7652 | PCSK9 | Human PCSK9 Antibody (RG7652, Research Use) | NBR-0829 |
| Schering patent anti-PCSK9 | PCSK9 | Human PCSK9 Antibody (Schering patent anti-PCSK9, Research Use) | NBR-0830 |
| Regeneron patent anti-ASIC1 | ASIC1 | Human ASIC1 Antibody (Regeneron patent anti-ASIC1, Research Use) | NBR-0831 |
| Balstilimab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Balstilimab, Research Use) | NBR-0832 |
| Budigalimab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Budigalimab, Research Use) | NBR-0833 |
| Cetrelimab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Cetrelimab, Research Use) | NBR-0834 |
| Regeneron patent anti-CD20 | CD20 | Human CD20 Antibody (Regeneron patent anti-CD20, Research Use) | NBR-0835 |
| Ezabenlimab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Ezabenlimab, Research Use) | NBR-0836 |
| Regeneron patent anti-EGFR | ERBB1 | Human ERBB1 / EGFR / HER1 Antibody (Regeneron patent anti-EGFR, Research Use) | NBR-0837 |
| Regeneron patent anti-PAR-2 | PAR2 | Human PAR2 Antibody (Regeneron patent anti-PAR-2, Research Use) | NBR-0838 |
| Penpulimab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Penpulimab, Research Use) | NBR-0839 |
| Pidilizumab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Pidilizumab, Research Use) | NBR-0840 |
| Pimivalimab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Pimivalimab, Research Use) | NBR-0841 |
| Retifanlimab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Retifanlimab, Research Use) | NBR-0842 |
| Sasanlimab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Sasanlimab, Research Use) | NBR-0843 |
| Serplulimab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Serplulimab, Research Use) | NBR-0844 |
| Sintilimab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Sintilimab, Research Use) | NBR-0845 |
| Tislelizumab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Tislelizumab, Research Use) | NBR-0846 |
| UCB patent anti-PD-1 | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (UCB patent anti-PD-1, Research Use) | NBR-0847 |
| Zimberelimab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Zimberelimab, Research Use) | NBR-0848 |
| Revdofilimab | TNFRSF4 | Human TNFRSF4 / OX40 / CD134 Antibody (Revdofilimab, Research Use) | NBR-0849 |
| RO5458640 | TNFSF12 | Human TNFSF12 / TWEAK Antibody (RO5458640, Research Use) | NBR-0850 |
| IMC-2C5 | PDGFRB | Human PDGFRB / CD140b Antibody (IMC-2C5, Research Use) | NBR-0851 |
| Robatumumab | IGF1R | Human IGF1R / CD221 Antibody (Robatumumab, Research Use) | NBR-0852 |
| Bavituximab | N/A | Human Phosphatidylserine Antibody (Bavituximab, Research Use) | NBR-0853 |
| Roche patent anti-ANG-2 | ANGPT2 | Human ANGPT2 Antibody (Roche patent anti-ANG-2, Research Use) | NBR-0854 |
| Roche patent anti-CCN1 | CCN1 | Human CYR61 / CCN1 Antibody (Roche patent anti-CCN1, Research Use) | NBR-0855 |
| BAY 1158061 | PRLR | Human PRLR / Prolactin Receptor Antibody (BAY 1158061, Research Use) | NBR-0856 |
| Rockefeller U. patent anti-Amyloid Beta | APP | Human Amyloid Beta Antibody (Rockefeller U. patent anti-Amyloid Beta, Research Use) | NBR-0857 |
| Roledumab | CD240d | Human RHD / CD240d Antibody (Roledumab, Research Use) | NBR-0858 |
| Medella patent anti-RAMP-3 | RAMP3 | Human RAMP3 Antibody (Medella patent anti-RAMP-3, Research Use) | NBR-0859 |
| LFB Anti-RhD | CD240d | Human RHD / CD240d Antibody (LFB Anti-RhD, Research Use) | NBR-0860 |
| Atinumab | RTN4 | Human RTN4 / NOGO Antibody (Atinumab, Research Use) | NBR-0861 |
| NG-101 | RTN4 | Human RTN4 / NOGO Antibody (NG-101, Research Use) | NBR-0862 |
| LK-1 | S100A4 | Human S100A4 Antibody (LK-1, Research Use) | NBR-0863 |
| SBI Biotech patent anti-BST2 | BST2 | Human BST2 / CD317 Antibody (SBI Biotech patent anti-BST2, Research Use) | NBR-0864 |
| AB-25E9 | SIGLEC15 | Human Siglec-15 / CD33L3 Antibody (AB-25E9, Research Use) | NBR-0865 |
| Medimmune patent anti-Siglec-15 | SIGLEC15 | Human Siglec-15 / CD33L3 Antibody (Medimmune patent anti-Siglec-15, Research Use) | NBR-0866 |
| Epratuzumab | CD22 | Human Siglec-2 / CD22 Antibody (Epratuzumab, Research Use) | NBR-0867 |
| NCI m971 | CD22 | Human Siglec-2 / CD22 Antibody (NCI m971, Research Use) | NBR-0868 |
| NCI m972 | CD22 | Human Siglec-2 / CD22 Antibody (NCI m972, Research Use) | NBR-0869 |
| Pinatuzumab | CD22 | Human Siglec-2 / CD22 Antibody (Pinatuzumab, Research Use) | NBR-0870 |
| IMGN779 | CD22 | Human Siglec-3 / CD33 Antibody (IMGN779, Research Use) | NBR-0871 |
| AzintuxizumAb | SLAMF7 | Human SLAMF7 / CS1 Antibody (AzintuxizumAb, Research Use) | NBR-0872 |
| PDL241 | SLAMF7 | Human SLAMF7 / CS1 Antibody (PDL241, Research Use) | NBR-0873 |
| VB1-050 | SLC2A8 | Human SLC2A8 Antibody (VB1-050, Research Use) | NBR-0874 |
| LifastuzumAb | SLC34A2 | Human SLC34A2 Antibody (LifastuzumAb, Research Use) | NBR-0875 |
| Upifitamab | SLC34A2 | Human SLC34A2 Antibody (Upifitamab, Research Use) | NBR-0876 |
| Solanezumab | APP | Human Amyloid Beta Antibody (Solanezumab, Research Use) | NBR-0877 |
| Sonepcizumab | SGPP1 | Human Sphingosine-1-phosphate Antibody (Sonepcizumab, Research Use) | NBR-0878 |
| Tadocizumab | ITGA2 & ITGB3 | Human Integrin a2b3 (ITGA2 & ITGB3) Antibody (Tadocizumab, Research Use) | NBR-0879 |
| Bepranemab | MAPT | Human Tau Antibody (Bepranemab, Research Use) | NBR-0880 |
| Tafolecimab | PCSK9 | Human PCSK9 Antibody (Tafolecimab, Research Use) | NBR-0881 |
| LY3022859 | TGFBR2 | Human TBFbR2 Antibody (LY3022859, Research Use) | NBR-0882 |
| NKTT320 | PTCRA | Human TCR Antibody (NKTT320, Research Use) | NBR-0883 |
| Telazorlimab | TNFRSF4 | Human TNFRSF4 / OX40 / CD134 Antibody (Telazorlimab, Research Use) | NBR-0884 |
| Tenatumomab | TNC | Human Tenascin C Antibody (Tenatumomab, Research Use) | NBR-0885 |
| Marstacimab | TFPI | Human TFPI Antibody (Marstacimab, Research Use) | NBR-0886 |
| NIS793 | TGFB1 | Human TGFb1 Antibody (NIS793, Research Use) | NBR-0887 |
| Zampilimab | TGM2 | Human TGM2 / Transglutaminase 2 Antibody (Zampilimab, Research Use) | NBR-0888 |
| Etigilimab | TIGIT | Human TIGIT Antibody (Etigilimab, Research Use) | NBR-0889 |
| Tesidolumab | C5 | Human Complement C5 Antibody (Tesidolumab, Research Use) | NBR-0890 |
| Theraclone patent anti-GM-CSF | CSF2 | Human CSF2 / GM-CSF Antibody (Theraclone patent anti-GM-CSF, Research Use) | NBR-0891 |
| Tilavonemab | MAPT | Human Tau Antibody (Tilavonemab, Research Use) | NBR-0892 |
| Chugai patent anti-TF | TF | Human Tissue factor / CD142 Antibody (Chugai patent anti-TF, Research Use) | NBR-0893 |
| Tilogotamab | TNFRSF10B | Human TNFRSF10B / TRAILR2 / CD262 Antibody (Tilogotamab, Research Use) | NBR-0894 |
| TNX-832 | TF | Human Tissue factor / CD142 Antibody (TNX-832, Research Use) | NBR-0895 |
| Benufutamab | TNFRSF10B | Human TNFRSF10B / TRAILR2 / CD262 Antibody (Benufutamab, Research Use) | NBR-0896 |
| TOL101 | PTCRA | Human TCR Antibody (TOL101, Research Use) | NBR-0897 |
| Lexatumumab | TNFRSF10B | Human TNFRSF10B / TRAILR2 / CD262 Antibody (Lexatumumab, Research Use) | NBR-0898 |
| Tomuzotuximab | ERBB1 | Human ERBB1 / EGFR / HER1 Antibody (Tomuzotuximab, Research Use) | NBR-0899 |
| Toray patent anti-Caprin-1 | CAPRIN1 | Human CAPRIN1 Antibody (Toray patent anti-Caprin-1, Research Use) | NBR-0900 |
| Toripalimab | PDCD1 | Human PDCD1 / PD-1 / CD279 Antibody (Toripalimab, Research Use) | NBR-0901 |
| BMS-986178 | TNFRSF4 | Human TNFRSF4 / OX40 / CD134 Antibody (BMS-986178, Research Use) | NBR-0902 |
| Torudokimab | IL-33 | Human IL-33 Antibody (Torudokimab, Research Use) | NBR-0903 |
| Tozorakimab | IL-33 | Human IL-33 Antibody (Tozorakimab, Research Use) | NBR-0904 |
| U.Illinois scFv59 | APP | Human Amyloid Beta Antibody (U.Illinois scFv59, Research Use) | NBR-0905 |
| Iscalimab | CD40 | Human TNFRSF5 / CD40 Antibody (Iscalimab, Research Use) | NBR-0906 |
| Lucatumumab | CD40 | Human TNFRSF5 / CD40 Antibody (Lucatumumab, Research Use) | NBR-0907 |
| Mitazalimab | CD40 | Human TNFRSF5 / CD40 Antibody (Mitazalimab, Research Use) | NBR-0908 |
| Ravagalimab | CD40 | Human TNFRSF5 / CD40 Antibody (Ravagalimab, Research Use) | NBR-0909 |
| U.Rochester patent anti-DC-STAMP | DCSTAMP | Human DCSTAMP Antibody (U.Rochester patent anti-DC-STAMP, Research Use) | NBR-0910 |
| Pateclizumab | TNFSF1 | Human TNFSF1 / TNFb Antibody (Pateclizumab, Research Use) | NBR-0911 |
| U.Washington patent anti-GAD65 | GAD2 | Human GAD65 Antibody (U.Washington patent anti-GAD65, Research Use) | NBR-0912 |
| U.Washington patent anti-MICB | MICB | Human MICB Antibody (U.Washington patent anti-MICB, Research Use) | NBR-0913 |
| Sibeprenlimab | TNFSF13 | Human TNFSF13 / APRIL / CD256 Antibody (Sibeprenlimab, Research Use) | NBR-0914 |
| Tabalumab | TNFSF13B | Human TNFSF13B / BAFF / CD257 Antibody (Tabalumab, Research Use) | NBR-0915 |
| SAR252067 | TNFSF14 | Human TNFSF14 / LIGHT / CD258 Antibody (SAR252067, Research Use) | NBR-0916 |
| CDP571 | TNFSF2 | Human TNFSF2 / TNFa Antibody (CDP571, Research Use) | NBR-0917 |
| U.Zurich patent anti-Amyloid Beta | APP | Human Amyloid Beta Antibody (U.Zurich patent anti-Amyloid Beta, Research Use) | NBR-0918 |
| CMAB008 | TNFSF2 | Human TNFSF2 / TNFa Antibody (CMAB008, Research Use) | NBR-0919 |
| ESBA 105 | TNFSF2 | Human TNFSF2 / TNFa Antibody (ESBA 105, Research Use) | NBR-0920 |
| HMAK195 | TNFSF2 | Human TNFSF2 / TNFa Antibody (HMAK195, Research Use) | NBR-0921 |
| Vedolizumab | ITGA4 & ITGB7 | Human Integrin a4b7 (ITGA4 & ITGB7) Antibody (Vedolizumab, Research Use) | NBR-0922 |
| Ruplizumab | CD40LG | Human TNFSF5 / CD40L / CD154 Antibody (Ruplizumab, Research Use) | NBR-0923 |
| Vibostolimab | TIGIT | Human TIGIT Antibody (Vibostolimab, Research Use) | NBR-0924 |
| Vilobelimab | C5 | Human Complement C5 Antibody (Vilobelimab, Research Use) | NBR-0925 |
| Wyeth patent anti-5T4 | TPBG | Human TPBG Antibody (Wyeth patent anti-5T4, Research Use) | NBR-0926 |
| Rinat patent anti-TrkB | NTRK2 | Human TrkB / NTRK2 Antibody (Rinat patent anti-TrkB, Research Use) | NBR-0927 |
| Schering patent anti-TSLP | TSLP | Human TSLP Antibody (Schering patent anti-TSLP, Research Use) | NBR-0928 |
| AGS67E | CD37 | Human TSPAN26 / CD37 Antibody (AGS67E, Research Use) | NBR-0929 |
| Volociximab | ITGA5 & ITGB1 | Human Integrin a5b1 (ITGA5 & ITGB1) Antibody (Volociximab, Research Use) | NBR-0930 |
| Vonlerizumab | TNFRSF4 | Human TNFRSF4 / OX40 / CD134 Antibody (Vonlerizumab, Research Use) | NBR-0931 |
| Hanwha patent anti-VCAM-1 | VCAM1 | Human VCAM1 / CD106 Antibody (Hanwha patent anti-VCAM-1, Research Use) | NBR-0932 |
| Zagotenemab | MAPT | Human Tau Antibody (Zagotenemab, Research Use) | NBR-0933 |
| Ranibizumab | VEGFA | Human VEGFA Antibody (Ranibizumab, Research Use) | NBR-0934 |
| Varisacumab | VEGFA | Human VEGFA Antibody (Varisacumab, Research Use) | NBR-0935 |
| VGX100 | VEGFC | Human VEGFC Antibody (VGX100, Research Use) | NBR-0936 |
| AlacizumAb | KDR | Human VEGFR2 / KDR / CD309 Antibody (AlacizumAb, Research Use) | NBR-0937 |
| AT001 | KDR | Human VEGFR2 / KDR / CD309 Antibody (AT001, Research Use) | NBR-0938 |
| Vulinacimab | KDR | Human VEGFR2 / KDR / CD309 Antibody (Vulinacimab, Research Use) | NBR-0939 |
| LY3022856 | FLT4 | Human VEGFR3 / FLT4 Antibody (LY3022856, Research Use) | NBR-0940 |
| Bapineuzumab | APP | Human Amyloid Beta Antibody (Bapineuzumab, Research Use) | NBR-0941 |
| Lecanemab | APP | Human Amyloid Beta Antibody (Lecanemab, Research Use) | NBR-0942 |
| Antitope patent anti-CTLA4 | CD152 | Human CTLA-4 / CD152 Antibody (Antitope patent anti-CTLA4, Research Use) | NBR-0943 |
| BioMab patent anti-Her2 | ERBB2 | Human ERBB2 / HER2 / CD340 Antibody (BioMab patent anti-Her2, Research Use) | NBR-0944 |
| BioMab patent anti-VEGF | VEGFA | Human VEGF Antibody (BioMab patent anti-VEGF, Research Use) | NBR-0945 |
| Centocor patent anti-GLP-1R | GLP1R | Human GLP1R Antibody (Centocor patent anti-GLP-1R, Research Use) | NBR-0946 |
| Axatilimab | CSF1R | Human CSF1R / M-CSFR / CD115 Antibody (Axatilimab, Research Use) | NBR-0947 |
| Immunomedics patent anti-CEACAM5 (Class III) | CD66a | Human CEACAM5 / CEA / CD66e Antibody (Immunomedics patent anti-CEACAM5 (Class III), Research Use) | NBR-0948 |
| Naxitamab |
| Human GD2 Antibody (Naxitamab, Research Use) | NBR-0949 |
| Medarex patent anti-IFNAR-1 | IFNAR1 | Human IFNARa1 Antibody (Medarex patent anti-IFNAR-1, Research Use) | NBR-0950 |
| Obexelimab | CD19 | Human CD19 Antibody (Obexelimab, Research Use) | NBR-0951 |
| Genzyme patent anti-TGF-β | TGFB1 | Human TGFb1 Antibody (Genzyme patent anti-TGF-β, Research Use) | NBR-0952 |
| Tezepelumab | TSLP | Human TSLP Antibody (Tezepelumab, Research Use) | NBR-0953 |
| IgG1+Kappa Isotype Control | ABM | Human Abm Antibody (IgG1+Kappa Isotype Control, Research Use) | NBR-0954 |
| IgG4+Kappa Isotype Control | ABM | Human Abm Antibody (IgG4+Kappa Isotype Control, Research Use) | NBR-0955 |
| Pritoxaximab | Shiga toxin (E.coli) | Human Shiga toxin (E.coli) Antibody (Pritoxaximab, Research Use) | NBR-0956 |
| Setoxaximab | Shiga toxin (E.coli) | Human Shiga toxin (E.coli) Antibody (Setoxaximab, Research Use) | NBR-0957 |
| OST 577 | HBsAg | Human HBsAg Antibody (OST 577, Research Use) | NBR-0958 |
| Foravirumab | Rabies virus GP | Human Rabies virus GP Antibody (Foravirumab, Research Use) | NBR-0959 |
| Rafivirumab | Rabies virus GP | Human Rabies virus GP Antibody (Rafivirumab, Research Use) | NBR-0960 |
| Motavizumab | RSV-F | Human RSV-F Antibody (Motavizumab, Research Use) | NBR-0961 |
| Palivizumab | RSV-F | Human RSV-F Antibody (Palivizumab, Research Use) | NBR-0962 |
| Metelimumab | TGFB1 | Human TGFB1 Antibody (Metelimumab, Research Use) | NBR-0963 |
| Bimekizumab | CTLA-8 | Human IL17A, IL-17F, IL17AF Antibody (Bimekizumab, Research Use) | NBR-0964 |
| Panitumumab | VEGF | Human EGFR Antibody (Panitumumab, Research Use) | NBR-0965 |
| Datopotamab | TACSTD2 | Human TROP2 Antibody (Datopotamab, Research Use) | NBR-0966 |
| Praluzatamab-MMAE | ALCAM / CD166 | Anti-ALCAM / CD166 Reference Antibody (Praluzatamab-MMAE) | NBR-1000 |
| Murlentamab-MMAE | AMHR2 | Anti-AMHR2 Reference Antibody (Murlentamab-MMAE) | NBR-1001 |
| Enapotamab vedotin | AXL / UFO | Anti-AXL / UFO Reference Antibody (Enapotamab vedotin) | NBR-1002 |
| Tilvestamab-MMAE | AXL / UFO | Anti-AXL / UFO Reference Antibody (Tilvestamab-MMAE) | NBR-1003 |
| oregovomab-MMAE | CA125 / MUC16 | Anti-MUC16 Reference Antibody (oregovomab-MMAE) | NBR-1004 |
| Sofituzumab vedotin | CA125 / MUC16 | Anti-MUC16 Reference Antibody (Sofituzumab vedotin) | NBR-1005 |
| girentuximab-MMAE | CA9 / Carbonic anhydrase 9 | Anti-CA9 / CAIX Reference Antibody (girentuximab-MMAE) | NBR-1006 |
| denintuzumab-MMAF | CD19 | Anti-CD19 Reference Antibody (denintuzumab-MMAF) | NBR-1007 |
| Polatuzumab vedotin-piiq | CD79b | Anti-CD79b Reference Antibody (Polatuzumab vedotin-piiq) | NBR-1008 |
| iladatuzumab vedotin | CD79b | Anti-CD79b Reference Antibody (iladatuzumab vedotin) | NBR-1009 |
| labetuzumab govitecan | CEACAM5 / CEA / CD66e | Anti-CEACAM5 / CEA / CD66e Reference Antibody (labetuzumab govitecan) | NBR-1010 |
| Tusamitamab-MMAE | CEACAM5 / CEA / CD66e | Anti-CEACAM5 / CEA / CD66e Reference Antibody (Tusamitamab-MMAE) | NBR-1011 |
| zolbetuximab MMAE | CLDN18.2 | Anti-CLDN18.2 Reference Antibody (zolbetuximab MMAE) | NBR-1012 |
| ulocuplumab-MMAE | CXCR4 / CD184 | Anti-CXCR4/CD184 Reference Antibody (ulocuplumab-MMAE) | NBR-1013 |
| rovalpituzumab-MMAE | DLL3 | Anti-DLL3 Reference Antibody (rovalpituzumab-MMAE) | NBR-1014 |
| carotuximab-MMAE | Endoglin / CD105 | Anti-Endoglin / CD105 Reference Antibody (carotuximab-MMAE) | NBR-1015 |
| depatuxizumab-MMAF | ERBB1 / EGFR / HER1 | Anti-ERBB1 / EGFR / HER1 Reference Antibody (depatuxizumab-MMAF) | NBR-1016 |
| Cetuximab-MMAE | ERBB1 / EGFR / HER1 | Anti-ERBB1 / EGFR / HER1 Reference Antibody (Cetuximab-MMAE) | NBR-1017 |
| Disitamab vedotin | ERBB2 / HER2 / CD340 | Anti-ERBB2 / HER2 / CD340 Reference Antibody (Disitamab vedotin) | NBR-1018 |
| Trastuzumab-MMAE | ERBB2 / HER2 / CD340 | Anti-ERBB2 / HER2 / CD340 Reference Antibody (Trastuzumab-MMAE) | NBR-1019 |
| patritumab-MMAE | ERBB3 / HER3 | Anti-ERBB3/ HER3 Reference Antibody (patritumab-MMAE) | NBR-1020 |
| Patritumab deruxtecan | ERBB3 / HER3 | Anti-ERBB3/ HER3 Reference Antibody (Patritumab deruxtecan) | NBR-1021 |
| rosopatamab-MMAE | FOLH1 / PSMA | Anti-FOLH1 / PSMA Reference Antibody (rosopatamab-MMAE) | NBR-1022 |
| farletuzumab-MMAE | FOLR1 / FRA | Anti-FOLR1 / FRA Reference Antibody (farletuzumab-MMAE) | NBR-1023 |
| mirvetuximab-MMAE | FOLR1 / FRA | Anti-FOLR1 / FRA Reference Antibody (mirvetuximab-MMAE) | NBR-1024 |
| ecromeximab-MMAE | GD3 | Anti-GD3 Reference Antibody (ecromeximab-MMAE) | NBR-1025 |
| Codrituzumab-MMAE | GPC3 / Glypican-3 | Anti-GPC3 / Glypican-3 Reference Antibody (Codrituzumab-MMAE) | NBR-1026 |
| Glembatumumab vedotin | GPNMB | Anti-GPNMB Reference Antibody (Glembatumumab vedotin) | NBR-1027 |
| Indusatumab vedotin | GUCY2C | Anti-GUCY2C Reference Antibody (Indusatumab vedotin) | NBR-1028 |
| Telisotuzumab vedotin | HGFR / c-Met | Anti-HGFR / c-Met Reference Antibody (Telisotuzumab vedotin) | NBR-1029 |
| talacotuzumab-MMAE | IL-3Ra / CD123 | Anti-IL-3Ra / CD123 Reference Antibody (talacotuzumab-MMAE) | NBR-1030 |
| ADCT-901-MMAE | KAAG1 | Anti-KAAG1 Reference Antibody (ADCT-901-MMAE) | NBR-1031 |
| Ladiratuzumab vedotin | LIV-1 / SLC39A6 | Anti-LIV-1 / SLC39A6 Reference Antibody (Ladiratuzumab vedotin) | NBR-1032 |
| anetumab-MMAE | Mesothelin | Anti-Mesothelin Reference Antibody (anetumab-MMAE) | NBR-1033 |
| ensituximab-MMAE | MU5AC | Anti-MU5AC Reference Antibody (ensituximab-MMAE) | NBR-1034 |
| clivatuzumab-MMAE | MUC1 | Anti-MUC1 Reference Antibody (clivatuzumab-MMAE) | NBR-1035 |
| Lifastuzumab vedotin | NaPi2b / SLC34A2 | Anti-NaPi2b / SLC34A2 Reference Antibody (Lifastuzumab vedotin) | NBR-1036 |
| lorvotuzumab-MMAE | NCAM1 / CD56 | Anti-NCAM1 / CD56 Reference Antibody (lorvotuzumab-MMAE) | NBR-1037 |
| enfortumab vedotin-ejfv | Nectin-4 | Anti-Nectin-4 Reference Antibody (enfortumab vedotin-ejfv) | NBR-1038 |
| Zilovertamab vedotin | ROR1 | Anti-ROR1 Reference Antibody (Zilovertamab vedotin) | NBR-1039 |
| ozuriftamab vedotin | ROR2 | Anti-ROR2 Reference Antibody (ozuriftamab vedotin) | NBR-1040 |
| Pinatuzumab vedotin | Siglec-2 / CD22 | Anti-Siglec-2 / CD22 Reference Antibody (Pinatuzumab vedotin) | NBR-1041 |
| inotuzumab-MMAE | Siglec-2 / CD22 | Anti-Siglec-2 / CD22 Reference Antibody (inotuzumab-MMAE) | NBR-1042 |
| Sirtratumab vedotin | SLITRK6 | Anti-SLITRK6 Reference Antibody (Sirtratumab vedotin) | NBR-1043 |
| tisotumab vedotin | TF / Factor III / Tissue Factor / CD142 | Anti-TF / Factor III / Tissue Factor / CD142 Reference Antibody (tisotumab vedotin) | NBR-1044 |
| brentuximab vedotin | TNFRSF8 / CD30 | Anti-TNFRSF8 / CD30 Reference Antibody (brentuximab vedotin) | NBR-1045 |
| Vorsetuzumab mafodotin | TNFSF7 / CD27L / CD70 | Anti-TNFSF7 / CD27L / CD70 Reference Antibody (Vorsetuzumab mafodotin) | NBR-1046 |
| datopotamab deruxtecan | TROP2 | Anti-TROP2 Reference Antibody (datopotamab deruxtecan) | NBR-1047 |
| Sacituzumab-MMAE | TROP2 | Anti-TROP2 Reference Antibody (Sacituzumab-MMAE) | NBR-1048 |
收缩
